[go: up one dir, main page]

JP2002060786A - Bactericidal antifouling agent for hard surfaces - Google Patents

Bactericidal antifouling agent for hard surfaces

Info

Publication number
JP2002060786A
JP2002060786A JP2000252284A JP2000252284A JP2002060786A JP 2002060786 A JP2002060786 A JP 2002060786A JP 2000252284 A JP2000252284 A JP 2000252284A JP 2000252284 A JP2000252284 A JP 2000252284A JP 2002060786 A JP2002060786 A JP 2002060786A
Authority
JP
Japan
Prior art keywords
group
carbon atoms
weight
alkyl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000252284A
Other languages
Japanese (ja)
Inventor
Shin Aihara
伸 相原
Noriyuki Morii
紀行 森井
Kazukuni Tsukuda
一訓 佃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Priority to JP2000252284A priority Critical patent/JP2002060786A/en
Priority to PCT/JP2001/006869 priority patent/WO2002016536A1/en
Priority to TW90120399A priority patent/TWI283267B/en
Publication of JP2002060786A publication Critical patent/JP2002060786A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/48Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D1/00Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
    • C11D1/38Cationic compounds
    • C11D1/62Quaternary ammonium compounds
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/37Polymers
    • C11D3/3746Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • C11D3/3769(Co)polymerised monomers containing nitrogen, e.g. carbonamides, nitriles or amines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

(57)【要約】 【課題】 家庭で使用でき、トイレ、浴室、台所まわり
などの硬質表面に対し、優れた殺菌性と防汚性の両方を
付与できる剤を提供する。 【解決手段】 (a)重量平均分子量が1,000〜
6,000,000であって、4級アンモニウム基を有
するモノマー単位の比率が全モノマー単位に対して10
〜100モル%である重合体、及び(b)分子量が1,
000未満であって、4級アンモニウム基を有する殺菌
性化合物を含有する硬質表面用殺菌防汚剤。
(57) [Problem] To provide an agent which can be used at home and can impart both excellent bactericidal properties and antifouling properties to hard surfaces such as toilets, bathrooms, and kitchen surroundings. (A) a weight average molecular weight of 1,000 to
6,000,000, and the ratio of monomer units having a quaternary ammonium group is 10
And (b) a molecular weight of 1,
A bactericidal antifouling agent for hard surfaces containing a bactericidal compound having a quaternary ammonium group, which is less than 000.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、硬質表面の殺菌、
及び防汚性、すなわち汚れの付着の防止、及び付着した
汚れを容易に除去することを可能にする硬質表面用の殺
菌防汚剤に関し、住居内全般、特に台所や浴室、トイ
レ、洗面台などの、壁や床、器具、機器などに使用した
際に、殺菌並びに汚れの付着防止及び易洗浄を可能にす
る硬表面用殺菌防汚剤に関する。
The present invention relates to sterilization of hard surfaces,
And anti-fouling property, that is, a bactericidal anti-fouling agent for hard surfaces that enables the prevention of the adhesion of dirt and the easy removal of the adhering dirt, in general in a house, especially kitchens, bathrooms, toilets, wash basins, etc. The present invention relates to a bactericidal and antifouling agent for hard surfaces which can be used for walls, floors, appliances, equipment, etc., and which can sterilize, prevent the adhesion of dirt, and easily clean.

【0002】[0002]

【従来の技術及び発明が解決しようとする課題】生活場
面では様々な場所で汚れが発生する。それらの汚れを除
去するために各種の洗浄剤が開発され、その洗浄力を強
化すべく検討がなされてきた。これら努力により、頑固
な汚れを落とすための手段が多く提案されている。
2. Description of the Related Art Dirt is generated in various places in a living scene. Various cleaning agents have been developed to remove such stains, and studies have been made to enhance their cleaning power. With these efforts, many means for removing stubborn dirt have been proposed.

【0003】また、このように汚れの除去性に優れた洗
浄剤を開発する一方で、汚れを付きにくくする技術及び
処理を施すことで付いた汚れを落とし易くする技術(以
後防汚性とする)に関する技術も多く検討されており、
洗浄剤として応用する技術が見出されている。例えば、
特開平2−145697号公報には、特定構造のスルホ
ベタイン型両性界面活性剤を配合する水洗トイレ用清浄
剤が、特開平3−35097号公報には、スルホコハク
酸ジエステルを含有する軟便付着防止性に優れ洗浄効果
の高い水性トイレ用清浄剤が、特開平10−1697号
公報には、特定の界面活性剤と水溶性溶剤を特定比率で
配合する洗浄剤が記載されている。特に、特開平9−1
69995号公報には、処理後の硬質表面に対する水の
接触角が30度以下となるような洗浄剤が優れた防汚性
を示し、具体的に、防汚基剤として、アニオン界面活性
剤と分子中に4級アンモニウム基を含む界面活性剤又は
水溶性ポリマーとの組み合わせが挙げられている。
[0003] In addition, while developing such a cleaning agent excellent in dirt removal properties, a technique for making dirt less likely to adhere and a technique for easily removing dirt attached by performing treatment (hereinafter referred to as antifouling property). ) Technologies are also being considered,
Techniques for application as cleaning agents have been found. For example,
JP-A-2-14597 discloses a flush toilet detergent containing a sulfobetaine-type amphoteric surfactant having a specific structure, and JP-A-3-35097 discloses a soft fecal adhesion-preventing agent containing a sulfosuccinic diester. Japanese Unexamined Patent Publication No. 10-1697 discloses a cleaning agent which is excellent in cleaning effect and has a high cleaning effect, in which a specific surfactant and a water-soluble solvent are mixed at a specific ratio. In particular, Japanese Patent Laid-Open No. 9-1
No. 69,995 discloses that a detergent having a water contact angle of 30 ° or less with a hard surface after treatment exhibits excellent antifouling property. Specifically, an anionic surfactant is used as an antifouling base. A combination with a surfactant containing a quaternary ammonium group in the molecule or a water-soluble polymer is mentioned.

【0004】以上のように、従来から防汚性に関する技
術は多く検討されてきている。しかしながら、従来の技
術は、水垢や便等の付着による汚れの発生を中心に抑制
するものであり、微生物やカビ由来の黒ずみに関する汚
れについては不十分である。加えて最近では、生活環境
の改善にともなって、目に見える汚れに加えて、衛生面
での問題を懸念する人が増えてきており、殺菌に対する
要求も高まってきている。
As described above, many techniques relating to antifouling properties have been studied. However, the conventional technology mainly suppresses the generation of stains due to adhesion of water scales and faeces, and is insufficient for stains related to darkening caused by microorganisms and mold. In addition, recently, with the improvement of the living environment, more and more people are concerned about hygiene problems in addition to visible stains, and the demand for sterilization is increasing.

【0005】このような殺菌に関する考え方として殺菌
剤の配合が提案される。しかしながら、家庭用に使用す
ることが一般的である殺菌剤を前記防汚剤に配合した場
合、防汚性と殺菌性の両方の効果を相殺してしまい、満
足できる殺菌性及び防汚性を達成することは極めて困難
であった。
[0005] As a concept regarding such sterilization, blending of a fungicide is proposed. However, when a disinfectant commonly used for home use is added to the antifouling agent, the effects of both the antifouling property and the bactericidal property are offset, and satisfactory bactericidal and antifouling properties are obtained. It was extremely difficult to achieve.

【0006】本発明の課題は、家庭で使用でき、トイ
レ、浴室、台所まわりなどの硬質表面に対し、殺菌性と
防汚性の両方を満足できる水準で付与できる剤を提供す
ることにある。
An object of the present invention is to provide an agent which can be used at home and which can impart both sterilizing and antifouling properties to hard surfaces such as toilets, bathrooms and kitchens at a satisfactory level.

【0007】[0007]

【課題を解決するための手段】本発明は、(a)重量平
均分子量が1,000〜6,000,000であって、
4級アンモニウム基を有するモノマー単位の比率が全モ
ノマー単位に対して10〜100モル%である重合体
〔以下、(a)成分という〕、及び(b)分子量が1,
000未満であって、4級アンモニウム基を有する殺菌
性化合物〔以下、(b)成分という〕を含有する硬質表
面用殺菌防汚剤に関する。ここで、殺菌とは抗菌の意味
も含むものとする。またモノマー単位とは、重合体を構
成しているモノマー由来のくり返し単位を指し、モノマ
ーとは重合体を作るもとになる低分子物質を指す。
According to the present invention, there is provided (a) a polymer having a weight average molecular weight of 1,000 to 6,000,000,
A polymer in which the ratio of the monomer unit having a quaternary ammonium group is 10 to 100 mol% based on all monomer units (hereinafter, referred to as component (a)), and (b) a molecular weight of 1,
The present invention relates to a bactericidal antifouling agent for hard surfaces containing a bactericidal compound having a quaternary ammonium group of less than 000 [hereinafter referred to as the component (b)]. Here, sterilization includes the meaning of antibacterial. Further, the monomer unit refers to a repeating unit derived from a monomer constituting the polymer, and the monomer refers to a low molecular substance from which the polymer is formed.

【0008】[0008]

【発明の実施の形態】本発明の(a)成分は、4級アン
モニウム基を有するモノマー単位(以下、モノマー単位
Aとする)を10〜100モル%含有する重合体であ
る。
BEST MODE FOR CARRYING OUT THE INVENTION The component (a) of the present invention is a polymer containing 10 to 100 mol% of a monomer unit having a quaternary ammonium group (hereinafter, referred to as monomer unit A).

【0009】モノマー単位Aは、4級アンモニウム基
(複数であってもよい)を含有するモノマー(以下、モ
ノマーAとする)を重合するか又は3級アミノ基(複数
であってもよい)を含有するモノマー(以下、モノマー
A’とする)を重合して得られるモノマー単位を4級ア
ンモニウム化することで得られる。
The monomer unit A is obtained by polymerizing a monomer containing a quaternary ammonium group (which may be plural) (hereinafter, referred to as monomer A) or by forming a tertiary amino group (which may be plural). It is obtained by subjecting a monomer unit obtained by polymerizing a contained monomer (hereinafter, referred to as monomer A ′) to quaternary ammonium.

【0010】モノマーAの好ましい例として、下記一般
式(4)の化合物を挙げることができる。
Preferred examples of the monomer A include a compound represented by the following general formula (4).

【0011】[0011]

【化3】 Embedded image

【0012】〔式中、R12、R13、R14は、それぞれ独
立して、水素原子、水酸基又は炭素数1〜3のアルキル
基である。Xは炭素数1〜12のアルキレン基、−CO
OR18−、−CONHR18−、−OCOR18−、−R19
−OCO−R18−から選ばれる基である。ここでR18
19は、それぞれ独立して、炭素数1〜5のアルキレン
基である。R15は炭素数1〜3のアルキル基もしくはヒ
ドロキシアルキル基又はR1213C=C(R14)−X−で
ある。R16は炭素数1〜3のアルキル基、ヒドロキシア
ルキル基、ベンジル基であり、R17はヒドロキシ基、カ
ルボキシル基、スルホン酸基もしくは硫酸エステル基で
置換されていてもよい炭素数1〜10のアルキル基又は
ベンジル基であり、R17がアルキル基、ヒドロキシアル
キル基又はベンジル基の場合は、Y-は陰イオンを示
す。また、R17がカルボキシル基、スルホン酸基、硫酸
エステル基を含む場合、Y-は存在せず、R17中のこれ
らの基は陰イオンとなる。Y-の陰イオンとしては、ハ
ロゲンイオン、硫酸イオン、炭素数1〜3のアルキル硫
酸エステルイオン、炭素数1〜3のアルキル基で置換さ
れていてもよい芳香族スルホン酸イオン、ヒドロキシイ
オンを挙げることができる。〕。
Wherein R 12 , R 13 and R 14 are each independently a hydrogen atom, a hydroxyl group or an alkyl group having 1 to 3 carbon atoms. X is an alkylene group having 1 to 12 carbon atoms, -CO
OR 18 -, - CONHR 18 - , - OCOR 18 -, - R 19
It is a group selected from —OCO—R 18 —. Where R 18 ,
R 19 is each independently an alkylene group having 1 to 5 carbon atoms. R 15 is an alkyl group or hydroxyalkyl group having 1 to 3 carbon atoms or R 12 R 13 C = C (R 14 ) —X—. R 16 is an alkyl group having 1 to 3 carbon atoms, a hydroxyalkyl group, or a benzyl group; and R 17 has 1 to 10 carbon atoms which may be substituted with a hydroxy group, a carboxyl group, a sulfonic acid group or a sulfate group. When R 17 is an alkyl group, a hydroxyalkyl group or a benzyl group, Y represents an anion. When R 17 contains a carboxyl group, a sulfonic acid group, or a sulfate group, Y does not exist, and these groups in R 17 become anions. Examples of the anion of Y include a halogen ion, a sulfate ion, an alkyl sulfate ion having 1 to 3 carbon atoms, an aromatic sulfonate ion optionally substituted by an alkyl group having 1 to 3 carbon atoms, and a hydroxy ion. be able to. ].

【0013】これらの中でもアクリロイル(又はメタク
リロイル)アミノアルキル(炭素数1〜5)−N,N,
N−トリアルキル(炭素数1〜3)4級アンモニウム
塩、アクリロイル(又はメタクリロイル)オキシアルキ
ル(炭素数1〜5)−N,N,N−トリアルキル(炭素
数1〜3)4級アンモニウム塩、N−(ω−アルケニル
(炭素数3〜10))−N,N,N−トリアルキル(炭
素数1〜3)4級アンモニウム塩、N,N−ジ(ω−ア
ルケニル(炭素数3〜10))−N,N−ジアルキル
(炭素数1〜3)4級アンモニウム塩が好ましく、特に
ジアリルジメチルアンモニウム塩が良好である。
Among them, acryloyl (or methacryloyl) aminoalkyl (C1-5) -N, N,
N-trialkyl (C1-3) quaternary ammonium salt, acryloyl (or methacryloyl) oxyalkyl (C1-5) -N, N, N-trialkyl (C1-3) quaternary ammonium salt , N- (ω-alkenyl (3 to 10 carbon atoms))-N, N, N-trialkyl (1 to 3 carbon atoms) quaternary ammonium salt, N, N-di (ω-alkenyl (3 to 10 carbon atoms) 10)) -N, N-dialkyl (C1-3) quaternary ammonium salts are preferred, and diallyldimethylammonium salts are particularly preferred.

【0014】モノマーA’の好ましい例として、下記一
般式(4’)の化合物を挙げることができる。
Preferred examples of the monomer A 'include a compound represented by the following general formula (4').

【0015】[0015]

【化4】 Embedded image

【0016】〔式中、R12、R13、R14、R15及びR16
は、前記記載と同じ。〕これらの中でもN,N−ジアル
キル(炭素数1〜3)アミノアルキル(炭素数1〜5)
アクリレート(又はメタクリレート)、N,N−ジアル
キル(炭素数1〜3)アミノアルキル(炭素数1〜5)
アクリルアミド、N,N−ジ(ω−アルケニル(炭素数
3〜10))−N−メチルアミンが好ましく、ジアリル
メチルアミンが特に好ましい。
Wherein R 12 , R 13 , R 14 , R 15 and R 16
Is the same as described above. Among them, N, N-dialkyl (C1-3) aminoalkyl (C1-5)
Acrylate (or methacrylate), N, N-dialkyl (C1-3) aminoalkyl (C1-5)
Acrylamide and N, N-di (ω-alkenyl (3 to 10 carbon atoms))-N-methylamine are preferred, and diallylmethylamine is particularly preferred.

【0017】モノマーA’を4級アンモニウム化する際
に用いられる4級化剤としては、メチルクロリド、メチ
ルブロミド、ベンジルクロリド、ジメチル硫酸、ジエチ
ル硫酸、モノクロロ酢酸又はその塩、クロルスルホン酸
又はその塩、3−クロロ−2−ヒドロキシプロパンスル
ホン酸又はその塩、エチレンオキシド、プロピレンオキ
シド、グリシジルエーテルなどを挙げることができる。
尚、エチレンオキシド、プロピレンオキシド、グリシジ
ルエーテルを使用する場合は、予め硫酸、塩酸、炭素数
1〜12のカルボン酸、アリルスルホン酸などでモノマ
ー単位を中和した後反応させることが好ましい。
The quaternizing agent used for converting the monomer A 'into a quaternary ammonium includes methyl chloride, methyl bromide, benzyl chloride, dimethyl sulfate, diethyl sulfate, monochloroacetic acid or a salt thereof, chlorosulfonic acid or a salt thereof. , 3-chloro-2-hydroxypropanesulfonic acid or a salt thereof, ethylene oxide, propylene oxide, glycidyl ether and the like.
When ethylene oxide, propylene oxide, or glycidyl ether is used, it is preferable that the monomer unit is neutralized with sulfuric acid, hydrochloric acid, a carboxylic acid having 1 to 12 carbon atoms, allylsulfonic acid, or the like before the reaction.

【0018】本発明の(a)成分は、モノマー単位A
(複数種であってもよい)からなる重合体のみならず、
モノマー単位A(複数種であってもよい)と他のモノマ
ー単位(以下、モノマー単位Bとする)とから構成され
た重合体であってもよい。(モノマーA’を使用する場
合は、アミン型のモノマー単位を有していてもよい。)
この場合、モノマー単位Aとモノマー単位B(複数種で
あってもよい)との配列様式は、ブロック、交互、周
期、統計(ランダムを含む)、グラフト型の何れであっ
てもよい。
The component (a) of the present invention comprises a monomer unit A
(May be plural kinds),
It may be a polymer composed of a monomer unit A (which may be plural kinds) and another monomer unit (hereinafter, referred to as a monomer unit B). (When the monomer A 'is used, it may have an amine type monomer unit.)
In this case, the arrangement of the monomer unit A and the monomer unit B (there may be plural types) may be any of block, alternating, periodic, statistical (including random), and graft type.

【0019】モノマー単位Aとモノマー単位Bとから構
成される重合体は、例えば、それぞれの前駆体モノマー
を共重合することによって得ることができる。この場
合、モノマー単位Bとしては、下記のモノマー群(i)
〜(v)から選ばれるモノマー由来のモノマー単位が好
ましく、(i)〜(iii)又は(v)記載のモノマー由
来のモノマー単位がより好ましく、特に防汚効果の点か
ら(i)、(ii)又は(v)のモノマー由来のモノマー
単位が最も好ましい。 (i)アクリル酸又はその塩、メタクリル酸又はその
塩、マレイン酸又はその塩、無水マレイン酸、スチレン
スルホン酸塩、スルホプロピルメタクリレート、2−ア
クリルアミド−2−メチルプロパンスルホン酸またはそ
の塩、リン酸モノ−ω−メタクリロイルオキシアルキル
(炭素数1〜12)から選ばれる陰イオン基含有化合物 (ii)アクリルアミド、N,N−ジメチルアミノプロピ
ルアクリル酸(又はメタクリル酸)アミド、N,N−ジ
メチルアクリル(又はメタクリル)アミド、N,N−ジ
メチルアミノエチルアクリル酸(又はメタクリル酸)ア
ミド、N,N−ジメチルアミノエチルアクリル酸(又は
メタクリル酸)アミド、N−ビニル−2−カプロラクタ
ム、N−ビニル−2−ピロリドンから選ばれるアミド基
含有化合物 (iii)アクリル酸(又はメタクリル酸)アルキル(炭
素数1〜5)、アクリル酸(又はメタクリル酸)2−ヒ
ドロキシエチル、アクリル酸(又はメタクリル酸)−
N,N−ジメチルアミノアルキル(炭素数1〜5)、酢
酸ビニルから選ばれるエステル基含有化合物 (iv)エチレン、プロピレン、N−ブチレン、イソブチ
レン、N−ペンテン、イソプレン、2−メチル−1−ブ
テン、N−ヘキセン、2−メチル−1−ペンテン、3−
メチル−1−ペンテン、4−メチル−1−ペンテン、2
−エチル−1−ブテン、スチレン、ビニルトルエン、α
−メチルスチレン、アリルアミン、N,N−ジアリルア
ミン、N,N−ジアリル−N−アルキル(炭素数1〜
5)アミン、エチレンオキシド、プロピレンオキシド、
2−ビニルピリジン、4−ビニルピリジンから選ばれる
化合物 (v)二酸化硫黄。
The polymer composed of the monomer units A and B can be obtained, for example, by copolymerizing the respective precursor monomers. In this case, as the monomer unit B, the following monomer group (i)
To (v) are preferred, and monomer units derived from the monomers described in (i) to (iii) or (v) are more preferred, and (i) and (ii) are particularly preferred from the viewpoint of antifouling effect. ) Or a monomer unit derived from the monomer (v) is most preferred. (I) acrylic acid or a salt thereof, methacrylic acid or a salt thereof, maleic acid or a salt thereof, maleic anhydride, styrene sulfonate, sulfopropyl methacrylate, 2-acrylamido-2-methylpropanesulfonic acid or a salt thereof, phosphoric acid Anionic group-containing compound selected from mono-ω-methacryloyloxyalkyl (C 1 to C 12) (ii) acrylamide, N, N-dimethylaminopropylacrylic acid (or methacrylic acid) amide, N, N-dimethylacryl ( Or methacryl) amide, N, N-dimethylaminoethylacrylic acid (or methacrylic acid) amide, N, N-dimethylaminoethylacrylic acid (or methacrylic acid) amide, N-vinyl-2-caprolactam, N-vinyl-2 -An amide group-containing compound selected from pyrrolidone (iii) Acrylic acid (or methacrylic acid) alkyl (C1-5), acrylic acid (or methacrylic acid) of 2-hydroxyethyl, acrylic acid (or methacrylic acid) -
An ester group-containing compound selected from N, N-dimethylaminoalkyl (1-5 carbon atoms) and vinyl acetate. (Iv) Ethylene, propylene, N-butylene, isobutylene, N-pentene, isoprene, 2-methyl-1-butene , N-hexene, 2-methyl-1-pentene, 3-
Methyl-1-pentene, 4-methyl-1-pentene, 2
-Ethyl-1-butene, styrene, vinyltoluene, α
-Methylstyrene, allylamine, N, N-diallylamine, N, N-diallyl-N-alkyl (having 1 to 1 carbon atoms)
5) amines, ethylene oxide, propylene oxide,
Compounds selected from 2-vinylpyridine and 4-vinylpyridine (v) Sulfur dioxide.

【0020】モノマー単位Aとモノマー単位Bを有する
重合体は前記のような共重合による合成方法の他、モノ
マー単位Aを含む重合体に前記(i)〜(iv)のモノマ
ー、特に好ましくは前記(i)、(ii)のモノマーをグ
ラフト重合して得てもよいし、前記(i)〜(iv)のモ
ノマーを含む重合体、特に好ましくは前記(i)、(i
i)のモノマーを含む重合体に前記一般式(4)のモノ
マーをグラフト重合して得てもよいし、前記(i)〜
(iv)のモノマーを含む重合体、特に好ましくは前記
(i)、(ii)のモノマーを含む重合体に前記一般式
(4’)のモノマーをグラフト重合した後、これを4級
化してもよい。
The polymer having the monomer unit A and the monomer unit B can be synthesized by the above-mentioned copolymerization method. Alternatively, the polymer containing the monomer unit A can be added to the monomers (i) to (iv), particularly preferably The polymer may be obtained by graft polymerization of the monomers (i) and (ii), or a polymer containing the monomers (i) to (iv), and particularly preferably the polymers (i) and (i).
The polymer containing the monomer of i) may be obtained by graft polymerization of the monomer of the general formula (4),
After graft-polymerizing the monomer of the general formula (4 ′) onto the polymer containing the monomer of (iv), particularly preferably the polymer containing the monomer of (i) or (ii), it is quaternized. Good.

【0021】本発明の(a)成分を構成する重合体はい
かなる重合法によって得てもよいが、ラジカル重合法が
特に好ましく、塊状、溶液、又は乳化系にてこれを行う
ことができる。ラジカル重合は加熱によりこれを開始し
てもよいが、開始剤として、2,2’−アゾビス(2−
アミジノプロパン)二塩酸塩、2,2’−アゾビス
(N,N−ジメチレンイソブチルアミジン)二塩酸塩、
などのアゾ系開始剤、過酸化水素及び、過酸化ベンゾイ
ル、t−ブチルヒドロパーオキシド、クメンヒドロパー
オキシド、メチルエチルケトンパーオキシド、過安息香
酸などの有機過酸化物、過硫酸ナトリウム、過硫酸カリ
ウム、過硫酸アンモニウムなどの過硫酸塩、過酸化水素
−Fe3+などのレドックス開始剤、など既存のラジカル
開始剤を用いてもよいし、光増感剤の存在/又は非存在
下での光照射や、放射線照射により重合を開始させても
よい。
The polymer constituting the component (a) of the present invention may be obtained by any polymerization method, but a radical polymerization method is particularly preferred, and the polymerization can be carried out in a bulk, solution or emulsion system. The radical polymerization may be initiated by heating, but 2,2′-azobis (2-
Amidinopropane) dihydrochloride, 2,2′-azobis (N, N-dimethyleneisobutylamidine) dihydrochloride,
Azo initiators such as hydrogen peroxide and benzoyl peroxide, t-butyl hydroperoxide, cumene hydroperoxide, methyl ethyl ketone peroxide, organic peroxides such as perbenzoic acid, sodium persulfate, potassium persulfate, An existing radical initiator such as a persulfate such as ammonium persulfate, a redox initiator such as hydrogen peroxide-Fe 3+ may be used, or light irradiation in the presence / absence of a photosensitizer or Alternatively, the polymerization may be started by irradiation with radiation.

【0022】本発明の(a)成分は、モノマー単位Aの
単一重合体並びにモノマー単位A及びモノマー単位Bの
コポリマーから選ばれる重合体の複数種の混合物であっ
てもよい。
The component (a) of the present invention may be a homopolymer of the monomer unit A or a mixture of a plurality of polymers selected from a copolymer of the monomer units A and B.

【0023】本発明の(a)成分における、モノマー単
位Aの割合は10〜100モル%であるが、より好まし
くは20〜100モル%である。
The proportion of the monomer unit A in the component (a) of the present invention is from 10 to 100 mol%, preferably from 20 to 100 mol%.

【0024】本発明の(a)成分は本発明の硬質表面用
殺菌防汚剤の殺菌性、防汚性を著しく阻害しない限りに
おいて、重合体Aを含有しない他の水溶性重合体を含有
していてもよい。
The component (a) of the present invention contains another water-soluble polymer which does not contain the polymer A, as long as the bactericidal and antifouling properties of the bactericidal and antifouling agent for hard surfaces of the present invention are not significantly impaired. May be.

【0025】本発明の(a)成分は重量平均分子量が
1,000〜6,000,000、好ましくは10,0
00〜6,000,000、特に好ましくは100,0
00〜6,000,000であり、この重量平均分子量
はアセトニトリルと水の混合溶媒(リン酸緩衝液)を展
開溶媒とし、ゲルパーミエーションクロマトグラフィー
でポリエチレングリコールを標準物質として求めたもの
である。
The component (a) of the present invention has a weight average molecular weight of 1,000 to 6,000,000, preferably 10,000.
00 to 6,000,000, particularly preferably 100,0
The weight average molecular weight is determined by gel permeation chromatography using polyethylene glycol as a standard substance using a mixed solvent of acetonitrile and water (phosphate buffer) as a developing solvent.

【0026】(a)成分は本発明の殺菌防汚剤中に好ま
しくは0.01〜30重量%、より好ましくは0.01
〜20重量%、最も好ましくは0.01〜10重量%含
有される。
The component (a) is preferably contained in the bactericidal antifouling agent of the present invention in an amount of 0.01 to 30% by weight, more preferably 0.01 to 30% by weight.
-20% by weight, most preferably 0.01-10% by weight.

【0027】本発明の(b)成分は、分子量が1000
未満、好ましくは500以下の少なくとも1つの4級ア
ンモニウム基を有する殺菌性化合物である。本発明でい
う殺菌性とは、下記方法により測定されるコロニー数が
10以下であることをいう。
The component (b) of the present invention has a molecular weight of 1,000.
Fungicidal compounds having at least one quaternary ammonium group of less than 500, preferably less than 500. The term "bactericidal" as used in the present invention means that the number of colonies measured by the following method is 10 or less.

【0028】<殺菌性測定方法>供試菌として大腸菌
(Escherichia coli:IFO397
2)と黄色ブドウ球菌(Staphylococcus
aureus IFO12732)を用いる。試験化合
物〔(b)成分〕の1重量%水溶液を調製し、該水溶液
2ml中に108〜109個の細菌浮遊液50μlを加え
よく混合した後、5分間放置する。放置後、この混合液
を0.1ml採取して0.9mlのLP希釈液中に加え
て十分混合し、前記化合物の菌への影響を低下させ、次
いでこの混合液をSCDLP寒天培地上に塗布し、大腸
菌は37℃で24時間、黄色ブドウ球菌は37℃で48
時間培養する。培養後の生育したコロニー数を数える。
なお殺菌試験は同じ化合物についてそれぞれ同時に5回
ずつ行う(5回×3)。この実験結果において、大腸菌
及び黄色ブドウ球菌の両方のコロニー数が10以下とな
るものを殺菌性ありとする。なお、前記規定以外の実験
条件の詳細は、防菌防黴ハンドブック(日本防菌防黴学
会編、技報堂出版)のp686に記載されている浮遊試
験法(定量的検査法)に従う。
<Method of measuring bactericidal property> Escherichia coli (IFO397) was used as a test bacterium.
2) and Staphylococcus
aureus IFO12732). A 1% by weight aqueous solution of the test compound [component (b)] is prepared, and 50 μl of 10 8 to 10 9 bacterial suspensions are added to 2 ml of the aqueous solution, mixed well, and allowed to stand for 5 minutes. After standing, 0.1 ml of this mixture is collected and added to 0.9 ml of LP diluent and mixed well to reduce the effect of the compound on the bacterium. Then, this mixture is applied on an SCDLP agar medium. E. coli for 24 hours at 37 ° C, Staphylococcus aureus for 48 hours at 37 ° C.
Incubate for hours. Count the number of grown colonies after culturing.
The bactericidal test is carried out simultaneously 5 times for the same compound (5 times 3). In this experimental result, those in which the number of colonies of both Escherichia coli and Staphylococcus aureus are 10 or less are regarded as bactericidal. The details of the experimental conditions other than the above-mentioned rules are based on the floating test method (quantitative test method) described in p.686 of the Bacterial and Fungicide Handbook (edited by the Japan Society of Bacterial and Fungicide, published by Gihodo).

【0029】(b)成分となる分子量1000未満の殺
菌性化合物としては、下記一般式(1)〜(3)で示さ
れる化合物が好ましく、それらのうち特に水溶性のもの
が好ましい。ここで水溶性とは20℃の水1Lに溶解す
る量が1g以上であることを指す。
As the fungicidal compound having a molecular weight of less than 1,000, which is the component (b), compounds represented by the following general formulas (1) to (3) are preferable, and among them, water-soluble compounds are particularly preferable. Here, the term "water-soluble" means that the amount dissolved in 1 L of water at 20 ° C is 1 g or more.

【0030】[0030]

【化5】 Embedded image

【0031】〔式中、R1及びR6は、それぞれ独立して
炭素数6〜18、好ましくは8〜16のアルキル基又は
アルケニル基、好ましくはアルキル基であり、R3及び
4は、それぞれ独立して炭素数1〜3のアルキル基又
はヒドロキシアルキル基である。Xは芳香環又は−CO
O−、−CONH−、−OCO−、−NHCO−から選
ばれるエステル基あるいはアミド基であり、R2は、X
がエステル基又はアミド基である場合には水酸基で置換
されていてもよい炭素数1〜6のアルキレン基であり、
Xが芳香環の場合には、水酸基で置換されていてもよい
炭素数1〜6のアルキレン基又は−(O−R11)k−であ
る。ここでR11はエチレン基又はプロピレン基、好まし
くはエチレン基であり、kは平均1〜10、好ましくは
平均1〜5の数である。R5は炭素数1〜3のアルキレ
ン基である。R7〜R10はこれらの内1つ以上、好まし
くは1つ又は2つが炭素数8〜18、好ましくは8〜1
4、より好ましくは8〜12のアルキル基であり、残り
が炭素数1〜3のアルキル基又はヒドロキシアルキル基
である。また、mは0又は1の数である。さらにY
-は、陰イオンであり、特にハロゲンイオン、硫酸イオ
ン、炭素数1〜3のアルキル硫酸イオン、炭素数1〜3
のアルキル基で置換されていてもよい芳香族スルホン酸
イオンが好ましい。〕。
Wherein R 1 and R 6 are each independently an alkyl or alkenyl group having 6 to 18 carbon atoms, preferably 8 to 16 carbon atoms, preferably an alkyl group, and R 3 and R 4 are Each is independently an alkyl group having 1 to 3 carbon atoms or a hydroxyalkyl group. X is an aromatic ring or -CO
O -, - CONH -, - OCO -, - is an ester group or amide group selected from NHCO-, R 2 is, X
Is an ester group or an amide group, is an alkylene group having 1 to 6 carbon atoms which may be substituted with a hydroxyl group,
When X is an aromatic ring, it is an alkylene group having 1 to 6 carbon atoms which may be substituted with a hydroxyl group, or-(OR 11 ) k- . Here, R 11 is an ethylene group or a propylene group, preferably an ethylene group, and k is a number of 1 to 10 on average, preferably 1 to 5 on average. R 5 is an alkylene group having 1 to 3 carbon atoms. R 7 to R 10 is one or more of these, preferably one or two C8 to C18, preferably 8-1
4, more preferably an alkyl group of 8 to 12, and the rest being an alkyl group having 1 to 3 carbon atoms or a hydroxyalkyl group. M is a number of 0 or 1. Further Y
- is an anion, especially a halide ion, sulfate ion, alkyl sulfate ion having 1 to 3 carbon atoms, 1 to 3 carbon atoms
Aromatic sulfonate ions which may be substituted with an alkyl group are preferred. ].

【0032】より好ましい(b)成分は上記一般式
(1)又は(3)の化合物であり、最も好ましくは下記
の一般式の化合物である。
More preferred component (b) is a compound of the above formula (1) or (3), most preferably a compound of the following formula.

【0033】[0033]

【化6】 Embedded image

【0034】(b)成分は本発明の殺菌防汚剤中に好ま
しくは0.001〜30重量%、より好ましくは0.0
01〜20重量%、最も好ましくは0.005〜5重量
%含有される。
Component (b) is preferably present in the fungicidal and antifouling agent of the present invention in an amount of 0.001 to 30% by weight, more preferably 0.01 to 30% by weight.
The content is from 0.01 to 20% by weight, most preferably from 0.005 to 5% by weight.

【0035】本発明において、充分な防汚性を保った上
で、殺菌効果を得るために(a)成分/(b)成分は重
量比で20/1〜1/50が好ましく、10/1〜1/
20がより好ましく、5/1〜1/10が最も好まし
い。
In the present invention, the weight ratio of component (a) / component (b) is preferably from 20/1 to 1/50 in order to obtain a bactericidal effect while maintaining sufficient antifouling properties. ~ 1 /
20 is more preferable, and 5/1 to 1/10 is most preferable.

【0036】本発明の硬質表面用殺菌防汚剤は、良好な
殺菌性及び防汚性を有するものであるが、更に(c)と
して(b)成分以外の界面活性剤〔以下、(c)成分と
いう〕を含有することで、洗浄性が付与され、硬質表面
用殺菌防汚洗浄剤として使用することができる。界面活
性剤としては、非イオン界面活性剤、両性界面活性剤、
陰イオン界面活性剤から選ばれる1種以上の界面活性剤
を添加することが好ましい。
The bactericidal and antifouling agent for hard surfaces of the present invention has good bactericidal and antifouling properties, and further comprises (c) a surfactant other than the component (b) [hereinafter referred to as (c) Component)], thereby imparting detergency and being able to be used as a hard surface sterilizing and antifouling detergent. As surfactants, nonionic surfactants, amphoteric surfactants,
It is preferable to add one or more surfactants selected from anionic surfactants.

【0037】非イオン界面活性剤としては、下記一般式
(c1)〜一般式(c3)の化合物が挙げられる。 Rc1−O(EO)nH (c1) 〔式中、Rc1は平均炭素数10〜20、好ましくは10
〜18の一級の直鎖アルキル基、分岐鎖アルキル基又は
二級のアルキル基である。EOはエチレンオキサイドで
あり、nは平均付加モル数として5〜20である。〕 Rc2−O(EO)p/(PO)qH (c2) 〔式中、Rc2は平均炭素数10〜20、好ましくは10
〜18の一級のアルキル基である。EOはエチレンオキ
サイド、POはプロピレンオキサイドを示す。k及びl
は平均付加モル数であり、pは5〜15、qは1〜5で
ある。EOとPOはランダム付加又はEOを付加した
後、POを付加してもよく、またその逆のようなブロッ
ク付加体でもよい。また、ブロック付加体は3つ以上の
ブロックであってもよい。〕 Rc3−(ORc4)xy (c3) 〔式中、Rc3は直鎖又は分岐鎖の炭素数8〜18のアル
キル基もしくはアルケニル基又は炭素数8〜18のアル
キル基を有するアルキルフェニル基、Rc4は炭素数2〜
4のアルキレン基、Gは炭素数5又は6の還元糖に由来
する残基好ましくはグルコース残基であり、xは平均値
0〜6の数、yは平均値1〜10の数を示す。〕。
Examples of the nonionic surfactant include compounds represented by the following general formulas (c1) to (c3). R c1 —O (EO) n H (c1) wherein R c1 has an average carbon number of 10 to 20, preferably 10
~ 18 primary linear alkyl group, branched alkyl group or secondary alkyl group. EO is ethylene oxide, and n is 5 to 20 as an average number of added moles. R c2 —O (EO) p / (PO) q H (c2) wherein R c2 has an average carbon number of 10 to 20, preferably 10
~ 18 primary alkyl groups. EO indicates ethylene oxide, and PO indicates propylene oxide. k and l
Is the average number of moles added, p is 5 to 15, and q is 1 to 5. EO and PO may be added randomly, or PO may be added after EO is added, or vice versa. Further, the block additional body may be three or more blocks. R c3- (OR c4 ) x G y (c3) wherein R c3 is a linear or branched alkyl group or alkenyl group having 8 to 18 carbon atoms or an alkyl group having an alkyl group having 8 to 18 carbon atoms. Phenyl group, R c4 has 2 to 2 carbon atoms
The alkylene group of 4, G is a residue derived from a reducing sugar having 5 or 6 carbon atoms, preferably a glucose residue, x represents a number having an average value of 0 to 6, and y represents a number having an average value of 1 to 10. ].

【0038】両性界面活性剤としては下記一般式(c
4)で表されるアミンオキシド及び一般式(c5)で表
されるベタインを挙げることができる。
As the amphoteric surfactant, the following general formula (c)
The amine oxide represented by 4) and betaine represented by the general formula (c5) can be exemplified.

【0039】[0039]

【化7】 Embedded image

【0040】〔式中、Rc5は炭素数8〜18のアルキル
基又はアルケニル基であり、Rc7、R c8は、それぞれ独
立して、炭素数1〜3のアルキル基又はヒドロキシアル
キル基である。Rc6は炭素数1〜5のアルキレン基であ
る。Aは−COO−、−CONH−、−OCO−、−N
HCO−、−O−から選ばれる基であり、rは0又は1
の数である。〕
[Wherein, Rc5Is alkyl having 8 to 18 carbon atoms
Or an alkenyl group,c7, R c8Is German
Standing, an alkyl group having 1 to 3 carbon atoms or hydroxyal
It is a kill group. Rc6Is an alkylene group having 1 to 5 carbon atoms
You. A represents -COO-, -CONH-, -OCO-, -N
HCO- or -O-, wherein r is 0 or 1
Is the number of ]

【0041】[0041]

【化8】 Embedded image

【0042】〔式中、Rc5、Rc6、Rc7、Rc8、A及び
rは前記一般式(c4)記載のものと同じである。Rc9
は水酸基で置換されていてもよい炭素数1〜5のアルキ
レン基であり、Tは−OSO3 -、−COO-、−SO3 -
から選ばれる陰イオン基である。rは0又は1の数であ
る。〕。
[Wherein R c5 , R c6 , R c7 , R c8 , A and r are the same as those described in the general formula (c4). R c9
Is an alkylene group of 1 to 5 carbon atoms which may be substituted with a hydroxyl group, T is -OSO 3 -, -COO -, -SO 3 -
An anionic group selected from r is a number of 0 or 1. ].

【0043】陰イオン界面活性剤としてはアルキル基の
炭素数8〜18のアルキルベンゼンスルホン酸塩、アル
カンスルホン酸塩、αオレフィンスルホン酸塩、アルキ
ル硫酸エステル塩、ポリオキシエチレンアルキルエーテ
ル硫酸塩、ポリオキシエチレンアルキルエーテル酢酸塩
等を挙げることができる。
Examples of the anionic surfactant include an alkylbenzene sulfonate having 8 to 18 carbon atoms, an alkane sulfonate, an α-olefin sulfonate, an alkyl sulfate, a polyoxyethylene alkyl ether sulfate, and a polyoxyalkylene sulfonate. Examples thereof include ethylene alkyl ether acetate.

【0044】本発明では特に前記一般式(c3)及び
(c4)から選ばれる界面活性剤の一種以上を配合する
ことが、防汚効果を損なうことなく優れた洗浄性を得る
上で好ましい。(c)成分の界面活性剤の配合量は、殺
菌及び防汚効果を損なうことなく十分な洗浄力を得るた
めに好ましくは0.01重量%以上、20重量%未満、
より好ましくは0.1重量%以上であり、特に好ましく
は0.1〜15重量%である。
In the present invention, it is particularly preferable to incorporate at least one of the surfactants selected from the general formulas (c3) and (c4) in order to obtain excellent detergency without impairing the antifouling effect. The amount of the surfactant (c) is preferably 0.01% by weight or more and less than 20% by weight in order to obtain a sufficient detergency without impairing the sterilizing and antifouling effects.
It is more preferably at least 0.1% by weight, particularly preferably from 0.1 to 15% by weight.

【0045】但し、陰イオン界面活性剤とベタイン型両
性界面活性剤(4級アンモニウム基と、スルホン酸基ま
たはカルボキシ基とを有する両性界面活性剤)は、殺菌
性及び防汚性を低下させるため、影響のない量で配合さ
れるべきであり、具体的には本発明の硬質表面用殺菌防
汚剤中5.0重量%を超えない量、より好ましくは3.
0重量%以下、最も好ましくは1.0重量%以下の量で
配合される。
However, anionic surfactants and betaine-type amphoteric surfactants (amphoteric surfactants having a quaternary ammonium group and a sulfonic acid group or a carboxy group) reduce bactericidal and antifouling properties. , In an amount that does not affect, specifically, an amount that does not exceed 5.0% by weight, more preferably 3.
0% by weight or less, most preferably 1.0% by weight or less.

【0046】本発明では、(d)成分として、有機汚れ
に対する洗浄力向上の目的で水溶性溶剤を配合すること
が好ましく、[1]炭素数1〜5の1価アルコール、
[2]炭素数4〜12の多価アルコール、[3]下記の
一般式(d1)で表される化合物、[4]下記の一般式
(d2)で表される化合物及び[5]下記の一般式(d
3)で表される化合物から選ばれる一種以上が好まし
い。
In the present invention, it is preferable to add a water-soluble solvent as component (d) for the purpose of improving the detergency against organic stains, [1] a monohydric alcohol having 1 to 5 carbon atoms,
[2] a polyhydric alcohol having 4 to 12 carbon atoms, [3] a compound represented by the following general formula (d1), [4] a compound represented by the following general formula (d2), and [5] the following The general formula (d
One or more compounds selected from the compounds represented by 3) are preferable.

【0047】[0047]

【化9】 Embedded image

【0048】〔式中、Rd1及びRd2は、それぞれ独立し
て、水素原子、炭素数1〜8のアルキル基、フェニル基
又はベンジル基を示すが、Rd11及びRd2の双方が水素
原子となる場合を除く。s及びtは、それぞれ独立し
て、0〜10の数を示すが、s及びtの双方が0である
場合を除く。Rd3及びRd4は炭素数1〜3のアルキル基
を示す。Rd5は炭素数1〜3のアルキル基を示す。〕。
[0048] wherein, R d1 and R d2 each independently represent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, but a phenyl group or a benzyl group, both R d1 1 and R d2 is a hydrogen Except when it becomes an atom. s and t each independently represent a number from 0 to 10, except when both s and t are 0. R d3 and R d4 each represent an alkyl group having 1 to 3 carbon atoms. R d5 represents an alkyl group having 1 to 3 carbon atoms. ].

【0049】[1]の炭素数2〜5の1価アルコールと
しては、一般的にエタノール、プロピルアルコール、イ
ソプロピルアルコールが挙げられる。これらの低級アル
コールを配合することにより低温における系の安定性を
更に向上させることができる。
The monohydric alcohol having 2 to 5 carbon atoms [1] generally includes ethanol, propyl alcohol and isopropyl alcohol. By incorporating these lower alcohols, the stability of the system at low temperatures can be further improved.

【0050】[2]の炭素数4〜12の多価アルコール
としては、イソプレングリコール、2,2,4−トリメ
チル−1,3−ペンタンジオール、1,8−オクタンジ
オール、1,9−ノナンジオール、エチレングリコー
ル、プロピレングリコール、ジエチレングリコール、ジ
プロピレングリコール、グリセリンの他、アルキル基の
炭素数が3〜8のモノアルキルグリセリルエーテル等が
挙げられる。
The polyhydric alcohol having 4 to 12 carbon atoms [2] includes isoprene glycol, 2,2,4-trimethyl-1,3-pentanediol, 1,8-octanediol, and 1,9-nonanediol , Ethylene glycol, propylene glycol, diethylene glycol, dipropylene glycol, glycerin, and monoalkyl glyceryl ether having an alkyl group having 3 to 8 carbon atoms.

【0051】[3]の化合物は、一般式(d1)におい
て、Rd1、Rd2がアルキル基である場合の炭素数は1〜
4が特に好ましい。また、一般式(d1)中、エチレン
オキサイド(以下、EOという)及びプロピレンオキサ
イド(以下、POという)の平均付加モル数のs及びt
は、それぞれ0〜10の数であるが、EOとPOの付加
順序は特に限定されず、ランダム付加したものであって
もよい。[3]の化合物の具体例としては、エチレング
リコールモノブチルエーテル、ジプロピレングリコール
ジメチルエーテル、ジエチレングリコールモノエチルエ
ーテル、ジエチレングリコールモノブチルエーテル、プ
ロピレングリコールモノメチルエーテル、プロピレング
リコールモノプロピルエーテル、プロピレングリコール
モノブチルエーテル、プロピレングリコールモノエチル
エーテル、プロピレングリコールジメチルエーテル、ポ
リオキシエチレン(平均付加モル数=2〜3)ポリオキ
シプロピレン(平均付加モル数=2〜3)グリコールジ
メチルエーテル、ポリオキシエチレン(平均付加モル数
=1〜4)グリコールフェニルエーテル、フェニルカル
ビトール、フェニルセロソルブ、ベンジルカルビトール
等が挙げられる。このうち、洗浄力及び使用感の点か
ら、プロピレングリコールモノメチルエーテル、ジエチ
レングリコールモノブチルエーテル、ポリオキシエチレ
ン(平均付加モル数=1〜4)グリコールフェニルエー
テルが好ましい。
The compound of [3] has a carbon number of 1 to 1 when R d1 and R d2 are alkyl groups in the general formula (d1).
4 is particularly preferred. Further, in the general formula (d1), s and t are average addition mole numbers of ethylene oxide (hereinafter, referred to as EO) and propylene oxide (hereinafter, referred to as PO).
Is a number from 0 to 10, respectively, but the order of addition of EO and PO is not particularly limited, and may be random addition. Specific examples of the compound [3] include ethylene glycol monobutyl ether, dipropylene glycol dimethyl ether, diethylene glycol monoethyl ether, diethylene glycol monobutyl ether, propylene glycol monomethyl ether, propylene glycol monopropyl ether, propylene glycol monobutyl ether, and propylene glycol monoethyl. Ether, propylene glycol dimethyl ether, polyoxyethylene (average addition mole number = 2-3) polyoxypropylene (average addition mole number = 2-3) glycol dimethyl ether, polyoxyethylene (average addition mole number = 1-4) glycol phenyl Ether, phenyl carbitol, phenyl cellosolve, benzyl carbitol and the like. Among these, propylene glycol monomethyl ether, diethylene glycol monobutyl ether, and polyoxyethylene (average number of moles = 1 to 4) glycol phenyl ether are preferred from the viewpoints of detergency and usability.

【0052】また、[4]の化合物としては、1,3−
ジメチル−2−イミダゾリジノン、1,3−ジエチル−
2−イミダゾリジノンが好適なものとして例示され、
[5]の化合物としては3−メトキシ−3−メチルブタ
ノール、3−エトキシ−3−メチルブタノール等が好ま
しい。
The compound of [4] includes 1,3-
Dimethyl-2-imidazolidinone, 1,3-diethyl-
2-imidazolidinone is exemplified as being preferred,
As the compound of [5], 3-methoxy-3-methylbutanol, 3-ethoxy-3-methylbutanol and the like are preferable.

【0053】これらのなかでも基材に対する損傷性の点
から[1]、[2]及び[3]の化合物から選ばれる水
溶性溶剤が好ましく、特にエタノール、イソプロピルア
ルコール、エチレングリコール、プロピレングリコー
ル、ジエチレングリコール、ジプロピレングリコール、
グリセリン、イソプレングリコール、プロピレングリコ
ールモノメチルエーテル、プロピレングリコールモノエ
チルエーテル、プロピレングリコールモノプロピルエー
テル、プロピレングリコールモノブチルエーテル及びア
ルキル基の炭素数が3〜8のモノアルキルグリセリルエ
ーテルから選ばれる水溶性溶剤が好ましい。
Among these, water-soluble solvents selected from the compounds [1], [2] and [3] are preferable from the viewpoint of damage to the substrate, and particularly ethanol, isopropyl alcohol, ethylene glycol, propylene glycol and diethylene glycol. , Dipropylene glycol,
A water-soluble solvent selected from glycerin, isoprene glycol, propylene glycol monomethyl ether, propylene glycol monoethyl ether, propylene glycol monopropyl ether, propylene glycol monobutyl ether and monoalkyl glyceryl ether having an alkyl group having 3 to 8 carbon atoms is preferable.

【0054】(d)成分の水溶性溶剤は、本発明の殺菌
性防汚剤中に好ましくは0.1〜20重量%、より好ま
しくは0.5〜10重量%、最も好ましくは1〜10重
量%含有される。
The water-soluble solvent of the component (d) is preferably 0.1 to 20% by weight, more preferably 0.5 to 10% by weight, most preferably 1 to 10% by weight in the germicidal antifouling agent of the present invention. % By weight.

【0055】本発明では無機汚れを溶解し、洗浄力及び
殺菌効果を向上させる目的で、さらに(e)成分とし
て、キレート剤を配合することが好ましい。キレート剤
としては(1)トリポリリン酸、ピロリン酸、オルソリ
ン酸、ヘキサメタリン酸及びこれらのアルカリ金属塩、
(2)エチレンジアミン四酢酸、ヒドロキシイミノ二酢
酸、ジヒドロキシエチルグリシン、ニトリロ三酢酸、ヒ
ドロキシエチレンジアミン三酢酸、ジエチレントリアミ
ン五酢酸、トリエチレンテトラミン六酢酸及びこれらの
アルカリ金属塩もしくはアルカリ土類金属塩、(3)ア
ミノトリメチレンホスホン酸、1−ヒドロキシエチリデ
ン−1,1−ジホスホン酸、エチレンジアミンテトラメ
チレンホスホン酸、ジエチレントリアミンペンタメチレ
ンホスホン酸、アミノトリメチレンホスホン酸のN−オ
キサイド及びこれらのアルカリ金属塩もしくはアルカリ
土類金属塩、(4)アクリル酸及びメタクリル酸から選
ばれるモノマーの単一重合体又は共重合体、アクリル酸
−マレイン酸共重合体、ポリα−ヒドロキアクリル酸及
びそのアルカリ金属塩、(5)クエン酸、コハク酸、リ
ンゴ酸、フマル酸、酒石酸、マロン酸、マレイン酸から
選ばれる多価カルボン酸及びそれらのアルカリ金属塩か
ら選ばれる1種以上、(6)アルキルグリシン−N,N
−ジ酢酸、アスパラギン酸−N,N−ジ酢酸、セリン−
N,N−ジ酢酸、グルタミン酸二酢酸、エチレンジアミ
ンジコハク酸又はこれらの塩が好ましく、特に(2)、
(3)、(5)の化合物が好ましい。
In the present invention, for the purpose of dissolving the inorganic soil and improving the detergency and the sterilizing effect, it is preferable to further add a chelating agent as the component (e). Examples of the chelating agent include (1) tripolyphosphoric acid, pyrophosphoric acid, orthophosphoric acid, hexametaphosphoric acid and alkali metal salts thereof,
(2) ethylenediaminetetraacetic acid, hydroxyiminodiacetic acid, dihydroxyethylglycine, nitrilotriacetic acid, hydroxyethylenediaminetriacetic acid, diethylenetriaminepentaacetic acid, triethylenetetraminehexaacetic acid and alkali metal salts or alkaline earth metal salts thereof, (3) N-oxides of aminotrimethylenephosphonic acid, 1-hydroxyethylidene-1,1-diphosphonic acid, ethylenediaminetetramethylenephosphonic acid, diethylenetriaminepentamethylenephosphonic acid, aminotrimethylenephosphonic acid and alkali metal salts or alkaline earth metals thereof Salt, (4) a homopolymer or copolymer of a monomer selected from acrylic acid and methacrylic acid, an acrylic acid-maleic acid copolymer, poly α-hydroxyacrylic acid and its alkali gold Salts, (5) one or more polycarboxylic acids selected from citric acid, succinic acid, malic acid, fumaric acid, tartaric acid, malonic acid, maleic acid and alkali metal salts thereof, and (6) alkylglycine- N, N
-Diacetic acid, aspartic acid-N, N-diacetic acid, serine-
N, N-diacetate, glutamic acid diacetate, ethylenediamine disuccinic acid or salts thereof are preferred, and particularly (2)
The compounds (3) and (5) are preferred.

【0056】(e)成分のキレート剤は、本発明の殺菌
性防汚剤中に好ましくは0.1〜20重量%、より好ま
しくは0.1〜10重量%、最も好ましくは0.5〜1
0重量%含有される。
The chelating agent of the component (e) is preferably 0.1 to 20% by weight, more preferably 0.1 to 10% by weight, most preferably 0.5 to 10% by weight in the germicidal antifouling agent of the present invention. 1
0% by weight is contained.

【0057】本発明は、pHを調整する場合にpH調整
剤を使用してもよい。pH調整剤としては塩酸や硫酸な
ど無機酸や、クエン酸、コハク酸、リンゴ酸、フマル
酸、酒石酸、マロン酸、マレイン酸などの有機酸などの
酸剤や、水酸化ナトリウムや水酸化カリウム、アンモニ
アやその誘導体、モノエタノールアミンやジエタノール
アミン、トリエタノールアミンなどのアミン塩など、炭
酸ナトリウム、炭酸カリウムなどのアルカリ剤を、単独
もしくは複合して用いても構わない。また、これらの酸
剤とアルカリ剤を組み合わせて緩衝剤系として用いても
構わない。
In the present invention, a pH adjuster may be used when adjusting the pH. Examples of the pH adjusting agent include inorganic acids such as hydrochloric acid and sulfuric acid, and acid agents such as citric acid, succinic acid, malic acid, fumaric acid, tartaric acid, malonic acid, maleic acid and other organic acids, sodium hydroxide and potassium hydroxide, Alkaline agents such as sodium carbonate and potassium carbonate such as ammonia and derivatives thereof, amine salts such as monoethanolamine, diethanolamine and triethanolamine may be used alone or in combination. Further, these acid agents and alkali agents may be used in combination as a buffer system.

【0058】本発明の硬表面用殺菌防汚剤は、上記のp
H調整剤により、20℃におけるpHが2〜12になる
ように調整することが好ましく、特にpH3〜11にな
るようにすることが防汚効果の点から好ましい。
The hard surface germicidal antifouling agent of the present invention comprises the above p
It is preferable to adjust the pH at 20 ° C. to 2 to 12 with an H adjuster, and it is particularly preferable to adjust the pH to 3 to 11 from the viewpoint of the antifouling effect.

【0059】本発明では使用時の付着性を持たせ使いや
すさ向上の目的で、水溶性高分子の1種以上を添加する
ことが出来る。水溶性高分子としては特に限定されるも
のではないが、特開平8−209194号公報6頁10
欄〜7頁11欄に記載の水溶性高分子から選ばれる1種
以上が好ましい。
In the present invention, one or more water-soluble polymers can be added for the purpose of imparting adhesion during use and improving ease of use. The water-soluble polymer is not particularly limited, but is disclosed in JP-A-8-209194, p.
Column 1 to page 7 column 11 are preferably one or more selected from the water-soluble polymers.

【0060】本発明の硬表面用殺菌防汚剤には、上記成
分の他に、本発明の効果を損なわない範囲で通常の洗浄
剤に配合されている添加剤、例えば香料、抗菌剤、粘度
調整剤、顔料、染料、懸濁剤などを添加することができ
る。また、使用時の起泡性を高める目的で、トルエンス
ルホン酸、キシレンスルホン酸、クメンスルホン酸、ア
ルケニルコハク酸及びこれらのアルカリ金属塩などの起
泡助剤から選ばれる1種以上を添加することが出来る。
The hard surface germicidal antifouling agent of the present invention includes, in addition to the above-mentioned components, additives incorporated in ordinary detergents as long as the effects of the present invention are not impaired, such as fragrances, antibacterial agents, and viscosities. Adjusters, pigments, dyes, suspending agents and the like can be added. Further, for the purpose of enhancing the foaming property at the time of use, at least one selected from foaming assistants such as toluenesulfonic acid, xylenesulfonic acid, cumenesulfonic acid, alkenylsuccinic acid and alkali metal salts thereof is added. Can be done.

【0061】本発明を使用する際には、(a)成分の重
合体と(b)成分の殺菌化合物とを、溶媒中に一剤とし
て溶解または分散させても、任意成分との組み合わせに
よる、任意の剤数にしても構わない。また、任意成分を
組み合わせることにより、水などの溶媒に対して、直ち
に溶解する、あるいは徐放性を付与した、一剤以上の粉
末や錠剤の形状で用いても構わない。さらに、(a)成
分と(b)成分、あるいは任意成分のいずれかが液状で
他方が粉末などの固体状で用いることもできる。
When the present invention is used, the polymer of the component (a) and the germicidal compound of the component (b) may be dissolved or dispersed as a single agent in a solvent, or may be used in combination with an optional component. Any number of agents may be used. In addition, by combining optional components, it may be used in the form of one or more powders or tablets which are immediately dissolved in a solvent such as water or provided with sustained release. Further, any one of the component (a) and the component (b) or the optional component may be used in a liquid state, and the other may be used in a solid state such as a powder.

【0062】本発明の殺菌防汚剤の使用時の形態は、特
に問わないが、(a)成分、(b)成分及び任意成分を
含有し残部が水の液体組成物か、またはポリエチレング
リコール、脂肪酸等の凝固剤を用いて固体状もしくはゲ
ル状の組成物としてもよい。本発明の殺菌防汚剤を液体
組成物として被洗浄対象である硬質表面に直接塗布する
ような場合は、該組成物中の(a)成分の含有量は、好
ましくは0.01〜10重量%、より好ましくは0.0
1〜5重量%、最も好ましくは0.01〜3重量%であ
り、(b)成分の含有量は、好ましくは0.001〜5
重量%、より好ましくは0.001〜3重量%、最も好
ましくは0.005〜3重量%であり、(c)成分の含
有量は、好ましくは0.01〜10重量%、より好まし
くは0.1〜8重量%、最も好ましくは0.1〜5重量
%であり、(d)成分の含有量は、好ましくは0.1〜
5重量%、より好ましくは0.5〜5重量%、最も好ま
しくは1〜3重量%であり、(e)成分の含有量は、好
ましくは0.1〜15重量%、より好ましくは0.1〜
10重量%、最も好ましくは0.5〜10重量%が好ま
しく、高い濃度の溶液を使用の直前に水道水などで希釈
することによって調製してもよい。また、これら液体組
成物には、壁面への付着性を上げるためにキサンタンガ
ム等の増粘剤を配合してもよい。なお、直接塗布する場
合は前記殺菌防汚剤ないしその洗浄剤を、被洗浄体へ直
接噴霧、散布又は塗布することができるトリガースプレ
ーヤーを備えた容器、またはスクイズ容器等の吐出機構
を有する容器に充填した物品とすることが最も好まし
い。
The mode of use of the germicidal antifouling agent of the present invention is not particularly limited, but is a liquid composition containing component (a), component (b) and optional components, with the balance being water or polyethylene glycol, A solid or gel composition may be prepared using a coagulant such as a fatty acid. When the germicidal antifouling agent of the present invention is directly applied as a liquid composition to a hard surface to be cleaned, the content of the component (a) in the composition is preferably 0.01 to 10% by weight. %, More preferably 0.0
The content of the component (b) is preferably 0.001 to 5% by weight, most preferably 0.01 to 3% by weight.
%, More preferably 0.001 to 3% by weight, most preferably 0.005 to 3% by weight, and the content of the component (c) is preferably 0.01 to 10% by weight, more preferably 0 to 10% by weight. 0.1 to 8% by weight, most preferably 0.1 to 5% by weight, and the content of the component (d) is preferably 0.1 to 5% by weight.
The content is 5% by weight, more preferably 0.5 to 5% by weight, most preferably 1 to 3% by weight, and the content of the component (e) is preferably 0.1 to 15% by weight, more preferably 0.1 to 15% by weight. 1 to
It is preferably 10% by weight, most preferably 0.5 to 10% by weight, and may be prepared by diluting a high concentration solution with tap water or the like immediately before use. Further, a thickener such as xanthan gum may be added to these liquid compositions in order to increase the adhesion to the wall surface. In the case of direct application, a container provided with a trigger sprayer capable of directly spraying, spraying or applying the sterilizing / fouling agent or the cleaning agent onto a body to be cleaned, or a container having a discharge mechanism such as a squeeze container It is most preferred that the article is filled with a.

【0063】また、固体状またはゲル状の場合は、トイ
レ水洗用タンクに用いるオートクリーナーとして有用で
ある。
In the case of a solid or gel, it is useful as an auto cleaner used for a toilet flush tank.

【0064】[0064]

【実施例】表1に示す組成の殺菌防汚剤を調製し、その
防汚性及び殺菌性について下記の方法で評価した。結果
を表1に示す。
EXAMPLES A bactericidal antifouling agent having the composition shown in Table 1 was prepared, and its antifouling property and bactericidal property were evaluated by the following methods. Table 1 shows the results.

【0065】<防汚性の評価> (1)易洗浄性 殺菌防汚剤1mLを、面積10cm2の陶器タイル表面
に塗布し、5分間放置した後、水200mLを45°の
角度で流速25mL/秒の割合で流し、乾燥させること
を5回繰り返して行った後、陶器タイル表面にスポット
状にオレイン酸を0.5g滴下する。オレイン酸を滴下
した陶器タイルを、オレイン酸が流れないよう、水槽の
底に静置し、陶器タイルに直接水がかからないよう、静
かに水槽中に水を満たしていく。その際のオレイン酸が
陶器タイル表面から除去される面積の割合を判定し、次
の5段階で評価した。なお、汚れ落ちの%はモデル汚染
板5枚の平均値を採用した。 5:汚れ落ちが80%以上である 4:汚れ落ちが60%以上80%未満である 3:汚れ落ちが40%以上60%未満である 2:汚れ落ちが20%以上40%未満である 1:汚れ落ちが20%未満である。
<Evaluation of antifouling property> (1) Easy cleaning property 1 mL of a sterilizing antifouling agent was applied to the surface of a ceramic tile having an area of 10 cm 2 , allowed to stand for 5 minutes, and then 200 mL of water was flowed at a 45 ° angle at a flow rate of 25 mL. After repeating the flow and drying at a rate of 5 times / second, 0.5 g of oleic acid is dropped on the surface of the ceramic tile in the form of spots. The ceramic tile with the oleic acid dropped on it is kept at the bottom of the water tank so that oleic acid does not flow, and the water is gently filled with water so that the ceramic tile is not directly exposed to water. At that time, the ratio of the area where oleic acid was removed from the surface of the ceramic tile was determined, and evaluated in the following five steps. In addition, the average value of five model-contaminated plates was adopted as the percentage of stain removal. 5: The stain removal is 80% or more 4: The stain removal is 60% or more and less than 80% 3: The stain removal is 40% or more and less than 60% 2: The stain removal is 20% or more and less than 40% 1. : Stain removal is less than 20%.

【0066】(2)汚れ付着防止性 市販の便器(C730B、東陶機器(株)製)を用い、
汚れの付きにくさの評価を行った。即ち組成物で便器を
洗浄し、1週間放置した際の汚れの付きにくさを、以下
の基準を基に肉眼で測定した。
(2) Antifouling property A commercially available toilet bowl (C730B, manufactured by TOTO Kiki Co., Ltd.) was used.
Evaluation of the difficulty of attaching dirt was performed. That is, the toilet was washed with the composition, and the degree of soiling when left for one week was visually measured based on the following criteria.

【0067】 (評価基準) ◎:汚れが付いていない。 ○:汚れが僅かに付いている。 △:汚れが少し付いている。 ×:汚れがかなり付いている。(Evaluation Criteria) A: There is no stain. :: Slightly adhered. Δ: Slightly adhered. ×: There is considerable dirt.

【0068】<殺菌性評価>供試菌として大腸菌(Es
cherichia coli:IFO3972)と黄
色ブドウ球菌(Staphylococcus aur
eus IFO12732)を用いた。
<Evaluation of bactericidal property> Escherichia coli (Es
cherichia coli (IFO3972) and Staphylococcus aur
eus IFO12732) was used.

【0069】殺菌性試験は、表1に示す殺菌防汚剤2m
l中に108〜109個の細菌浮遊液50μlを加えよく
混合した後、放置時間を5分とした時の殺菌性を調べ
た。放置後、その混合液を0.1ml採取して0.9m
lのLP希釈液中に加えて十分混合し、洗浄液の菌への
影響を低下させ、次いでこの混合液をSCDLP寒天培
地上に塗布し、大腸菌は37℃で24時間、黄色ブドウ
球菌は37℃で48時間培養する。培養後の生育したコ
ロニー数を数える。なお殺菌試験は、同じ殺菌防汚剤に
ついて、各放置時間毎にそれぞれ5つの試験区により行
ない、以下の評点で殺菌性を評価した。
The bactericidal test was carried out using 2 m of the germicidal antifouling agent shown in Table 1.
After 50 μl of 10 8 to 10 9 bacterial suspensions were added and mixed well, the bactericidal activity when the standing time was set to 5 minutes was examined. After standing, 0.1 ml of the mixture was collected and 0.9 m
1 L of LP diluent and mixed well to reduce the effect of the washings on the bacteria, then apply this mixture on SCDLP agar medium for 24 hours at 37 ° C for E. coli and 37 ° C for Staphylococcus aureus. And culture for 48 hours. Count the number of grown colonies after culturing. In addition, the sterilization test performed the same sterilization antifouling agent by five test sections each for each leaving time, and evaluated the sterilization by the following scores.

【0070】なお、前記規定以外の実験条件の詳細は、
防菌防黴ハンドブック(日本防菌防黴学会編、技報堂出
版)のp686に記載されている浮遊試験法(定量的検
査法)に従う。 ○:放置時間が5分でのコロニー数が104以下にな
る。 ×:放置時間が5分でのコロニー数が104を超える
The details of the experimental conditions other than the above-mentioned rules were as follows.
The floating test method (quantitative test method) described in p.686 of the Bactericidal and Fungicide Handbook (edited by the Japan Society of Bacterial and Fungicide, published by Gihodo). :: The number of colonies after leaving for 5 minutes is 10 4 or less. ×: The number of colonies in a standing time of 5 minutes exceeds 10 4

【0071】[0071]

【表1】 [Table 1]

【0072】・重合体A:マーコート550[塩化ジア
リルジメチルアンモニウムとアクリルアミド(モル比3
0/70)共重合体(Calgon社製、重量平均分子
量500万、ゲルパーミエーションクロマトグラムによ
り測定、ポリエチレングリコールを標準として使用)] ・重合体B:マーコート100[塩化ジアリルジメチル
アンモニウムのホモポリマー(Calgon社製、重量
平均分子量40万、ゲルパーミエーションクロマトグラ
ムで測定、ポリエチレングリコールを標準として使
用)] ・殺菌性化合物A:サニゾールC[ココアルキルジメチ
ルベンジルアンモニウムクロリド(花王(株)製)] ・殺菌性化合物B:コータミンD10P[ジデシルジメ
チルアンモニウムクロリド(花王(株)製)] ・殺菌性化合物C:塩化ベンゼトニウム[和光試薬、下
記構造のカチオン化合物]
Polymer A: Mercoat 550 [diallyldimethylammonium chloride and acrylamide (molar ratio 3
0/70) Copolymer (manufactured by Calgon, weight average molecular weight 5,000,000, measured by gel permeation chromatogram, using polyethylene glycol as a standard)] Polymer B: Mercoat 100 [diallyldimethylammonium chloride homopolymer ( Calgon, weight average molecular weight: 400,000, measured by gel permeation chromatogram, using polyethylene glycol as a standard)] Bactericidal compound A: Sanisole C [cocoalkyldimethylbenzylammonium chloride (manufactured by Kao Corporation)] Fungicidal compound B: Cotamine D10P [didecyldimethylammonium chloride (manufactured by Kao Corporation)] Fungicidal compound C: Benzethonium chloride [Wako reagent, cationic compound having the following structure]

【0073】[0073]

【化10】 Embedded image

【0074】・AO:アンヒトール20N[ラウリルジ
メチルアミンオキシド(花王(株)製)] ・AG:アルキルグルコシド(直鎖アルキル基の炭素数
が12と14の混合物、糖平均縮合度1.2[縮合度1
と2の混合物]) ・ES:EO平均付加モル数が2.2モルのポリオキシ
エチレンラウリルエーテル硫酸 ・ベタイン:N−ラウロイルアミノプロピル−N,N−
ジメチル−N−カルボキシメチルアンモニウムベタイン ・EDTA−4Na:エチレンジアミン四酢酸四ナトリ
ウム塩 ・pH調整剤:塩酸及び/又は水酸化ナトリウム(何れ
も水溶液で用いる)
AO: Amphitol 20N [lauryl dimethylamine oxide (manufactured by Kao Corporation)] AG: Alkyl glucoside (a mixture of straight-chain alkyl groups having 12 to 14 carbon atoms, average sugar condensation degree 1.2 [condensation] Degree 1
And 2]) ES: polyoxyethylene lauryl ether sulfate having an average addition mole number of 2.2 mol betaine: N-lauroylaminopropyl-N, N-
Dimethyl-N-carboxymethylammonium betaine EDTA-4Na: tetrasodium ethylenediaminetetraacetate pH adjuster: hydrochloric acid and / or sodium hydroxide (all used in aqueous solution)

───────────────────────────────────────────────────── フロントページの続き (72)発明者 佃 一訓 和歌山県和歌山市湊1334 花王株式会社研 究所内 Fターム(参考) 4H003 AC05 AC08 AC15 AD04 AE05 AE06 AE08 BA12 DA05 DA17 EA03 EA21 EB08 EB16 EB28 EB30 EB32 ED02 ED28 FA06 FA28 FA34  ──────────────────────────────────────────────────続 き Continuing on the front page (72) Inventor Kazunori Tsukuda 1334 Minato, Wakayama City, Wakayama Pref. ED02 ED28 FA06 FA28 FA34

Claims (4)

【特許請求の範囲】[Claims] 【請求項1】 (a)重量平均分子量が1,000〜
6,000,000であって、4級アンモニウム基を有
するモノマー単位の比率が全モノマー単位に対して10
〜100モル%である重合体、及び(b)分子量が1,
000未満であって、4級アンモニウム基を有する殺菌
性化合物を含有する硬質表面用殺菌防汚剤。
(1) a weight average molecular weight of 1,000 to
6,000,000, and the ratio of monomer units having a quaternary ammonium group is 10
And (b) a molecular weight of 1,
A bactericidal antifouling agent for hard surfaces containing a bactericidal compound having a quaternary ammonium group, which is less than 000.
【請求項2】 (b)が下記一般式(1)〜(3)で表
される化合物から選ばれる一種以上の殺菌性化合物であ
る請求項1記載の硬質表面用殺菌防汚剤。 【化1】 〔式中、R1及びR6は、それぞれ独立して炭素数6〜1
8のアルキル基又はアルケニル基であり、R3及びR
4は、それぞれ独立して炭素数1〜3のアルキル基又は
ヒドロキシアルキル基である。Xは芳香環又は−COO
−、−CONH−、−OCO−、−NHCO−から選ば
れるエステル基あるいはアミド基であり、R2は、Xが
エステル基又はアミド基である場合には水酸基で置換さ
れていてもよい炭素数1〜6のアルキレン基であり、X
が芳香環の場合には、水酸基で置換されていてもよい炭
素数1〜6のアルキレン基又は−(O−R11)k−であ
る。ここでR11はエチレン基又はプロピレン基であり、
kは平均1〜10の数である。R5は炭素数1〜3のア
ルキレン基である。R7〜R10はこれらの内1つ以上が
炭素数8〜18のアルキル基であり、残りが炭素数1〜
3のアルキル基又はヒドロキシアルキル基である。ま
た、mは0又は1の数である。さらにY-は、陰イオン
である。〕
2. The germicidal and antifouling agent for hard surfaces according to claim 1, wherein (b) is one or more germicidal compounds selected from the compounds represented by the following general formulas (1) to (3). Embedded image [Wherein, R 1 and R 6 each independently represent a carbon number of 6 to 1 ;
8 alkyl or alkenyl groups, and R 3 and R
4 is independently an alkyl group or a hydroxyalkyl group having 1 to 3 carbon atoms. X is an aromatic ring or -COO
—, —CONH—, —OCO—, or —NHCO—, an ester group or an amide group, and R 2 represents a carbon number which may be substituted with a hydroxyl group when X is an ester group or an amide group. 1 to 6 alkylene groups;
Is an aromatic ring, it is an alkylene group having 1 to 6 carbon atoms which may be substituted with a hydroxyl group, or-(OR 11 ) k- . Here, R 11 is an ethylene group or a propylene group,
k is a number of 1 to 10 on average. R 5 is an alkylene group having 1 to 3 carbon atoms. In R 7 to R 10 , at least one of them is an alkyl group having 8 to 18 carbon atoms, and the rest is a C 1 to C 1 alkyl group.
3 alkyl groups or hydroxyalkyl groups. M is a number of 0 or 1. Further, Y is an anion. ]
【請求項3】 (a)の4級アンモニウム基を有するモ
ノマー単位が、下記一般式(4)の化合物に由来する請
求項1記載の硬質表面用殺菌防汚剤。 【化2】 〔式中、R12、R13、R14は、それぞれ独立して、水素
原子、水酸基又は炭素数1〜3のアルキル基である。X
は炭素数1〜12のアルキレン基、−COOR18−、−
CONHR18−、−OCOR18−、−R19−OCO−R
18−から選ばれる基である。ここでR18、R19は、それ
ぞれ独立して、炭素数1〜5のアルキレン基である。R
15は炭素数1〜3のアルキル基もしくはヒドロキシアル
キル基又はR1213C=C(R14)−X−である。R16
炭素数1〜3のアルキル基、ヒドロキシアルキル基、ベ
ンジル基であり、R17はヒドロキシ基、カルボキシル
基、スルホン酸基もしくは硫酸エステル基で置換されて
いてもよい炭素数1〜10のアルキル基又はベンジル基
であり、R17がアルキル基、ヒドロキシアルキル基又は
ベンジル基の場合は、Y-は陰イオンを示す。また、R
17がカルボキシル基、スルホン酸基、硫酸エステル基を
含む場合、Y-は存在せず、R17中のこれらの基は陰イ
オンとなる。〕
3. The disinfectant / fouling agent for hard surfaces according to claim 1, wherein the monomer unit having a quaternary ammonium group in (a) is derived from a compound represented by the following general formula (4). Embedded image [In the formula, R 12 , R 13 , and R 14 are each independently a hydrogen atom, a hydroxyl group, or an alkyl group having 1 to 3 carbon atoms. X
Is an alkylene group having 1 to 12 carbon atoms, -COOR 18 -,-
CONHR 18 -, - OCOR 18 - , - R 19 -OCO-R
18- . Here, R 18 and R 19 are each independently an alkylene group having 1 to 5 carbon atoms. R
15 hydroxy or alkyl group having 1 to 3 carbon atoms alkyl or R 12 R 13 C = C ( R 14) is -X-. R 16 is an alkyl group having 1 to 3 carbon atoms, a hydroxyalkyl group, or a benzyl group; and R 17 has 1 to 10 carbon atoms which may be substituted with a hydroxy group, a carboxyl group, a sulfonic acid group or a sulfate group. When R 17 is an alkyl group, a hydroxyalkyl group or a benzyl group, Y represents an anion. Also, R
When 17 contains a carboxyl group, a sulfonic acid group, or a sulfate group, Y 2 - is not present, and these groups in R 17 become anions. ]
【請求項4】 更に(c)として、(b)以外の界面活
性剤を0.01重量%以上20重量%未満(但し、組成
物中の陰イオン界面活性剤及びベタイン型両性界面活性
剤の合計量は5.0重量%を超えない)の濃度で含有す
る請求項1〜3何れか一項記載の硬質表面用殺菌防汚洗
浄剤。
4. Further, as (c), 0.01% by weight or more and less than 20% by weight of a surfactant other than (b) (provided that an anionic surfactant and a betaine-type amphoteric surfactant in the composition are used). The germicidal and antifouling detergent for hard surfaces according to any one of claims 1 to 3, which is contained at a concentration of not more than 5.0% by weight.
JP2000252284A 2000-08-23 2000-08-23 Bactericidal antifouling agent for hard surfaces Pending JP2002060786A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000252284A JP2002060786A (en) 2000-08-23 2000-08-23 Bactericidal antifouling agent for hard surfaces
PCT/JP2001/006869 WO2002016536A1 (en) 2000-08-23 2001-08-09 Bactericidal antifouling detergent for hard surface
TW90120399A TWI283267B (en) 2000-08-23 2001-08-20 Bactericidal antifouling detergent for hard surface

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000252284A JP2002060786A (en) 2000-08-23 2000-08-23 Bactericidal antifouling agent for hard surfaces

Publications (1)

Publication Number Publication Date
JP2002060786A true JP2002060786A (en) 2002-02-26

Family

ID=18741548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000252284A Pending JP2002060786A (en) 2000-08-23 2000-08-23 Bactericidal antifouling agent for hard surfaces

Country Status (3)

Country Link
JP (1) JP2002060786A (en)
TW (1) TWI283267B (en)
WO (1) WO2002016536A1 (en)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004075789A (en) * 2002-08-14 2004-03-11 Kao Corp Cleaning composition for hard surfaces
JP2004155803A (en) * 2002-11-01 2004-06-03 Kao Corp Solid detergent composition for flush toilet
JP2005029756A (en) * 2003-07-11 2005-02-03 Kao Corp Toilet cleaner
JP2005029754A (en) * 2003-07-11 2005-02-03 Kao Corp Aqueous liquid composition
WO2008054009A1 (en) 2006-10-31 2008-05-08 Kao Corporation Bleaching agent composition
JP2008266375A (en) * 2007-04-17 2008-11-06 Johnson Diversey Co Ltd Cleaning composition for hard surface
JP2010168428A (en) * 2009-01-20 2010-08-05 Kao Corp Liquid detergent composition for hard surface
JP2011246677A (en) * 2010-05-31 2011-12-08 Ueno Fine Chem Ind Ltd Cleaning-sterilizing agent composition
JP2012092320A (en) * 2010-09-28 2012-05-17 Kobayashi Pharmaceutical Co Ltd Biofilm removing agent, composition for removing biofilm, and method for removing biofilm
JP2012111846A (en) * 2010-11-25 2012-06-14 Dainippon Jochugiku Co Ltd Acidic antibacterial detergent composition
JP2012193287A (en) * 2011-03-17 2012-10-11 Adeka Corp Detergent composition for oil stain
JP2012255073A (en) * 2011-06-08 2012-12-27 Kao Corp Liquid detergent composition for hard surface
JP2013023642A (en) * 2011-07-25 2013-02-04 Dainippon Jochugiku Co Ltd Rinse accelerator for hard surface detergent
JP2014009349A (en) * 2012-07-03 2014-01-20 Kao Corp Liquid aroma composition for flush toilet
JP2015507676A (en) * 2011-12-29 2015-03-12 バイオトロル・ピーエルシー Antimicrobial composition
JP2015113455A (en) * 2013-12-16 2015-06-22 花王株式会社 Sterilizing detergent composition for hard surfaces
JP2016124965A (en) * 2014-12-26 2016-07-11 ライオン株式会社 Liquid cleaner for bathroom
JP2017048238A (en) * 2010-12-31 2017-03-09 バイオトロル・ピーエルシー Antimicrobial composition
JP2019156999A (en) * 2018-03-14 2019-09-19 株式会社ニイタカ Detergent composition, spray bottle, wet wiper, and deodorization and sterilization cleaning method
WO2019199886A1 (en) * 2018-04-09 2019-10-17 Rhodia Operations Compositions and methods for long lasting disinfection
JP2020041074A (en) * 2018-09-12 2020-03-19 ライオン株式会社 Liquid detergent composition for clothing
JP2020100691A (en) * 2018-12-20 2020-07-02 中国塗料株式会社 Antifouling coat composition, antifouling coat film, base material with antifouling coat film, antifouling method for base material and method for producing base material with antifouling coat film
JP2020152856A (en) * 2019-03-22 2020-09-24 株式会社Adeka Cleaning agent composition for hard surface and cleaning method for hard surface

Families Citing this family (325)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4230153B2 (en) * 2002-02-22 2009-02-25 花王株式会社 Antifouling cleaner for hard surfaces
DE60316117T2 (en) 2002-02-22 2008-05-29 Kao Corp. CLEANING AGENT WITH ANTIFOULING PROPERTIES FOR HARD SURFACES
US20120196370A1 (en) 2010-12-03 2012-08-02 Fyodor Urnov Methods and compositions for targeted genomic deletion
DK2927318T3 (en) 2003-08-08 2020-08-03 Sangamo Therapeutics Inc Method and compositions for targeted cleavage and recombination
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
JP2005232241A (en) * 2004-02-18 2005-09-02 Toyo Aluminium Foil Products Kk Coating agent for removing greasy dirt
KR20070060115A (en) 2004-09-16 2007-06-12 상가모 바이오사이언스 인코포레이티드 Compositions and Methods for Protein Production
WO2007014275A2 (en) 2005-07-26 2007-02-01 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences
CA2651494C (en) 2006-05-25 2015-09-29 Sangamo Biosciences, Inc. Engineered cleavage half-domains
CA2651499C (en) 2006-05-25 2015-06-30 Sangamo Biosciences, Inc. Methods and compositions for ccr-5 gene inactivation
CA2660485C (en) 2006-08-11 2016-04-12 Sangamo Biosciences, Inc. Zinc finger nuclease-mediated homologous recombination
CA2667414C (en) * 2006-11-13 2015-12-29 Sangamo Biosciences, Inc. Methods and compositions for modification of the human glucocorticoid receptor locus
ES2586210T3 (en) 2006-12-14 2016-10-13 Sangamo Biosciences, Inc. Optimized non-canon zinc finger proteins
AU2008244473B2 (en) 2007-04-26 2013-06-20 Sangamo Therapeutics, Inc. Targeted integration into the PPP1R12C locus
EP2171052B1 (en) 2007-07-12 2014-08-27 Sangamo BioSciences, Inc. Methods and compositions for inactivating alpha 1,6 fucosyltransferase (fut 8) gene expression
US11235026B2 (en) 2007-09-27 2022-02-01 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
SI2205749T1 (en) 2007-09-27 2016-09-30 Dow Agrosciences, Llc Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes
US9506120B2 (en) 2007-09-27 2016-11-29 Sangamo Biosciences, Inc. Rapid in vivo identification of biologically active nucleases
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
US8936936B2 (en) 2007-10-25 2015-01-20 Sangamo Biosciences, Inc. Methods and compositions for targeted integration
JP2011518555A (en) 2008-04-14 2011-06-30 サンガモ バイオサイエンシーズ, インコーポレイテッド Linear donor constructs for targeted integration
DK2268129T3 (en) 2008-04-21 2015-09-28 Danziger Innovations Ltd PLANTEVIRUSEKSPRESSIONSVEKTORER AND USE THEREOF FOR GENERATING GENOTYPEVARIATIONER into plant genomes
AU2009260888B2 (en) 2008-05-28 2014-09-11 Sangamo Therapeutics, Inc. Compositions for linking DNA-binding domains and cleavage domains
EP2294191B1 (en) 2008-06-10 2016-09-28 Sangamo BioSciences, Inc. Methods and compositions for generation of bax- and bak-deficient cell lines
US8703489B2 (en) 2008-08-22 2014-04-22 Sangamo Biosciences, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration
EP2344660B1 (en) 2008-10-29 2018-01-17 Sangamo Therapeutics, Inc. Methods and compositions for inactivating glutamine synthetase gene expression
CN102625655B (en) 2008-12-04 2016-07-06 桑格摩生物科学股份有限公司 Zinc finger nuclease is used to carry out genome editor in rats
CA2747124C (en) 2008-12-17 2018-09-04 Dow Agrosciences Llc Targeted integration into the zp15 locus
JP5827132B2 (en) 2009-02-04 2015-12-02 サンガモ バイオサイエンシズ インコーポレイテッド Methods and compositions for treating neuropathy
US8871905B2 (en) 2009-03-20 2014-10-28 Sangamo Biosciences, Inc. Modification of CXCR4 using engineered zinc finger proteins
EP2419511B1 (en) 2009-04-09 2018-01-17 Sangamo Therapeutics, Inc. Targeted integration into stem cells
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
AU2010266705B2 (en) 2009-06-30 2014-06-05 Sangamo Therapeutics, Inc. Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
JP5866283B2 (en) 2009-07-28 2016-02-17 サンガモ バイオサイエンシーズ, インコーポレイテッド Methods and compositions for treating trinucleotide repeat disease
NZ619886A (en) 2009-08-11 2015-03-27 Sangamo Biosciences Inc Organisms homozygous for targeted modification
WO2011048600A1 (en) 2009-10-21 2011-04-28 Danziger Innovations Ltd. Generating genotypic variations in plant genomes by gamete infection
RU2568056C2 (en) 2009-10-22 2015-11-10 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Constructed proteins with zinc fingers directed towards genes of plants involved in biosynthesis of fatty acids
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
PH12012501491B1 (en) 2010-01-22 2019-06-28 Dow Agrosciences Llc Targeted genomic alteration
CA2788560A1 (en) 2010-02-08 2011-08-11 Sangamo Biosciences, Inc. Engineered cleavage half-domains
CA2788850C (en) 2010-02-09 2019-06-25 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
SG185367A1 (en) 2010-04-26 2012-12-28 Sangamo Biosciences Inc Genome editing of a rosa locus using zinc-finger nucleases
HRP20200254T1 (en) 2010-05-03 2020-05-29 Sangamo Therapeutics, Inc. PREPARATIONS FOR CONNECTING ZINC FINGER MODULE
EP2596011B1 (en) 2010-07-21 2018-10-03 Sangamo Therapeutics, Inc. Methods and compositions for modification of a hla locus
EP2622090B1 (en) 2010-09-27 2019-06-19 Sangamo Therapeutics, Inc. Compositions for inhibiting viral entry into cells
WO2012051343A1 (en) 2010-10-12 2012-04-19 The Children's Hospital Of Philadelphia Methods and compositions for treating hemophilia b
US9267123B2 (en) 2011-01-05 2016-02-23 Sangamo Biosciences, Inc. Methods and compositions for gene correction
AU2012286901B2 (en) 2011-07-25 2016-10-27 Sangamo Therapeutics, Inc. Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
IL277027B (en) 2011-09-21 2022-07-01 Sangamo Therapeutics Inc Methods and preparations for regulating transgene expression
US8895264B2 (en) 2011-10-27 2014-11-25 Sangamo Biosciences, Inc. Methods and compositions for modification of the HPRT locus
US9458205B2 (en) 2011-11-16 2016-10-04 Sangamo Biosciences, Inc. Modified DNA-binding proteins and uses thereof
RU2639277C2 (en) 2012-02-29 2017-12-20 Сангамо Байосайенсиз, Инк. Methods and compositions for huntington disease treatment
DK2839013T3 (en) 2012-04-18 2020-09-14 Univ Leland Stanford Junior NON-DISRUPTIVE-GEN-TARGETING
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
MX369788B (en) 2012-05-02 2019-11-21 Dow Agrosciences Llc Targeted modification of malate dehydrogenase.
EP2847338B1 (en) 2012-05-07 2018-09-19 Sangamo Therapeutics, Inc. Methods and compositions for nuclease-mediated targeted integration of transgenes
DK2872625T3 (en) 2012-07-11 2017-02-06 Sangamo Biosciences Inc METHODS AND COMPOSITIONS FOR TREATING LYSOSOMAL STORAGE DISEASES
US10648001B2 (en) 2012-07-11 2020-05-12 Sangamo Therapeutics, Inc. Method of treating mucopolysaccharidosis type I or II
WO2014011901A2 (en) 2012-07-11 2014-01-16 Sangamo Biosciences, Inc. Methods and compositions for delivery of biologics
CA2882499C (en) 2012-08-29 2023-09-26 Sangamo Biosciences, Inc. Cells genetically modified within the bcl11a gene by a nuclease and various aspects related thereto
UA118090C2 (en) 2012-09-07 2018-11-26 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
UA119135C2 (en) 2012-09-07 2019-05-10 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Engineered transgene integration platform (etip) for gene targeting and trait stacking
EP2893006B1 (en) 2012-09-07 2018-08-22 Dow AgroSciences LLC Fad3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
AU2013329186B2 (en) 2012-10-10 2019-02-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
AU2013355327A1 (en) 2012-12-05 2015-06-11 Sangamo Therapeutics, Inc. Methods and compositions for regulation of metabolic disorders
AR093980A1 (en) 2012-12-13 2015-07-01 Dow Agrosciences Llc PRECISION GENES THAT HAVE A PARTICULAR LOCUS IN THE CORN AS THE OBJECTIVE
JP6491113B2 (en) 2013-02-25 2019-03-27 サンガモ セラピューティクス, インコーポレイテッド Methods and compositions for enhancing nuclease-mediated gene disruption
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
AU2014235968B2 (en) 2013-03-21 2018-05-24 Ospedale San Raffaele Srl Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
KR102223568B1 (en) 2013-04-05 2021-03-04 다우 아그로사이언시즈 엘엘씨 Methods and compositions for integration of an exogenous sequence within the genome of plants
CA2910489A1 (en) 2013-05-15 2014-11-20 Sangamo Biosciences, Inc. Methods and compositions for treatment of a genetic condition
WO2015031619A1 (en) 2013-08-28 2015-03-05 Sangamo Biosciences, Inc. Compositions for linking dna-binding domains and cleavage domains
CN116836957A (en) 2013-10-17 2023-10-03 桑格摩生物科学股份有限公司 Delivery methods and compositions for nuclease-mediated genome engineering
CA2926078C (en) 2013-10-17 2021-11-16 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
BR102014027466B1 (en) 2013-11-04 2022-09-27 Dow Agrosciences Llc RECOMBINANT NUCLEIC ACID MOLECULE, METHOD FOR PRODUCING A TRANSGENIC PLANT CELL AND USES OF A SOYBEAN PLANT, PART OF A SOYBEAN PLANT, OR A TRANSGENIC SOYBEAN PLANT CELL
JP6634022B2 (en) 2013-11-04 2020-01-22 ダウ アグロサイエンシィズ エルエルシー Optimal soybean loci
AU2014341929B2 (en) 2013-11-04 2017-11-30 Corteva Agriscience Llc Optimal maize loci
EP3066110B1 (en) 2013-11-04 2021-12-29 Corteva Agriscience LLC Optimal maize loci
KR102431079B1 (en) 2013-11-11 2022-08-11 상가모 테라퓨틱스, 인코포레이티드 Methods and compositions for treating huntington's disease
EP3960856A1 (en) 2013-11-13 2022-03-02 Children's Medical Center Corporation Nuclease-mediated regulation of gene expression
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
AU2014363991B2 (en) 2013-12-09 2020-08-27 Sangamo Therapeutics, Inc. Methods and compositions for genome engineering
DK3102673T3 (en) 2014-02-03 2020-07-06 Sangamo Therapeutics Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF BETA-TALASSEMI
WO2015127439A1 (en) 2014-02-24 2015-08-27 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration
TW201538518A (en) 2014-02-28 2015-10-16 Dow Agrosciences Llc Root specific expression conferred by chimeric gene regulatory elements
WO2015143046A2 (en) 2014-03-18 2015-09-24 Sangamo Biosciences, Inc. Methods and compositions for regulation of zinc finger protein expression
WO2015143177A1 (en) 2014-03-21 2015-09-24 The Board Of Trustees Of The Leland Stanford Junior University Genome editing without nucleases
WO2015153889A2 (en) 2014-04-02 2015-10-08 University Of Florida Research Foundation, Incorporated Materials and methods for the treatment of latent viral infection
WO2015171932A1 (en) 2014-05-08 2015-11-12 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
CA2947622A1 (en) 2014-05-13 2015-11-19 Sangamo Biosciences, Inc. Genome editing methods and compositions for prevention or treatment of a disease
EP3152319A4 (en) 2014-06-05 2017-12-27 Sangamo BioSciences, Inc. Methods and compositions for nuclease design
CA2954201A1 (en) 2014-07-08 2016-01-14 Vib Vzw Means and methods to increase plant yield
BR112017000925B1 (en) 2014-07-14 2023-10-10 Washington State University METHOD OF REPRODUCTION OF PIGS, METHOD OF GENERATING A PIG WITHOUT ANY FUNCTIONAL SPERMATOGONE CELLS, METHOD OF PRODUCING A RECEIVING MALE AND METHOD OF PRODUCING PIGS
CA2954414A1 (en) 2014-07-15 2016-01-21 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
US11278572B2 (en) 2014-07-18 2022-03-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reducing CXCR4 expression and/or function to enhance engraftment of hematopoietic stem cells
WO2016014794A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
WO2016014837A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Gene editing for hiv gene therapy
US9616090B2 (en) 2014-07-30 2017-04-11 Sangamo Biosciences, Inc. Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
HUE055583T2 (en) 2014-09-16 2021-12-28 Sangamo Therapeutics Inc Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
US10889834B2 (en) 2014-12-15 2021-01-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing targeted transgene integration
HK1246690A1 (en) 2015-01-21 2018-09-14 Sangamo Therapeutics, Inc. Methods and compositions for identification of highly specific nucleases
JP6800859B2 (en) 2015-01-26 2020-12-16 フェイト セラピューティクス,インコーポレイテッド Methods and Compositions for Inducing Hematopoietic Cell Differentiation
US10676726B2 (en) 2015-02-09 2020-06-09 Duke University Compositions and methods for epigenome editing
EP3277823B1 (en) 2015-04-03 2023-09-13 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
RU2017137599A (en) 2015-04-15 2019-05-15 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи VEGETABLE PROMOTER FOR THE TRANSGEN EXPRESSION
WO2016168229A1 (en) 2015-04-15 2016-10-20 Dow Agrosciences Llc Plant promoter for transgene expression
US11845928B2 (en) 2015-05-04 2023-12-19 Tsinghua University Methods and kits for fragmenting DNA
US10179918B2 (en) 2015-05-07 2019-01-15 Sangamo Therapeutics, Inc. Methods and compositions for increasing transgene activity
CA2984013A1 (en) 2015-05-12 2016-11-17 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
WO2016196388A1 (en) 2015-05-29 2016-12-08 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
US9957501B2 (en) 2015-06-18 2018-05-01 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
CN108024544B (en) 2015-07-13 2022-04-29 桑格摩生物治疗股份有限公司 Delivery methods and compositions for nuclease-mediated genome engineering
MA42895A (en) 2015-07-15 2018-05-23 Juno Therapeutics Inc MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
SI3331355T1 (en) 2015-08-06 2024-10-30 The Curators Of The University Of Missouri Porcine reproductive and respiratory syndrome virus (prrsv)-resistant porcine and cells having modified cd163 genes
TW201718862A (en) 2015-09-22 2017-06-01 Dow Agrosciences Llc Plant promoter and 3' UTR for transgene expression
TW201718861A (en) 2015-09-22 2017-06-01 道禮責任有限公司 Plant promoter and 3'UTR for transgene expression
JP6853257B2 (en) 2015-09-23 2021-03-31 サンガモ セラピューティクス, インコーポレイテッド HTT repressor and its use
EP4089175A1 (en) 2015-10-13 2022-11-16 Duke University Genome engineering with type i crispr systems in eukaryotic cells
US10280429B2 (en) 2015-10-22 2019-05-07 Dow Agrosciences Llc Plant promoter for transgene expression
AU2016349504B2 (en) 2015-11-04 2023-02-09 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
KR20250033315A (en) 2015-11-04 2025-03-07 페이트 세러퓨틱스, 인코포레이티드 Methods and compositions for inducing hematopoietic cell differentiation
WO2017078935A1 (en) 2015-11-04 2017-05-11 Dow Agrosciences Llc Plant promoter for transgene expression
US10639383B2 (en) 2015-11-23 2020-05-05 Sangamo Therapeutics, Inc. Methods and compositions for engineering immunity
EA201891317A3 (en) 2015-11-30 2019-04-30 Дьюк Юниверсити THERAPEUTIC TARGETS FOR CORRECTION OF HUMAN DISTROPHIN GENE BY EDITING GENES AND METHODS OF THEIR APPLICATION
IL259935B2 (en) 2015-12-18 2023-03-01 Sangamo Therapeutics Inc Targeted disruption of the mhc cell receptor
AU2016369490C1 (en) 2015-12-18 2021-12-23 Sangamo Therapeutics, Inc. Targeted disruption of the T cell receptor
CA3010738A1 (en) 2016-01-15 2017-07-20 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of neurologic disease
KR20180101442A (en) 2016-02-02 2018-09-12 상가모 테라퓨틱스, 인코포레이티드 Compositions for linking DNA-binding domains and cleavage domains
WO2017165655A1 (en) 2016-03-23 2017-09-28 Dana-Farber Cancer Institute, Inc. Methods for enhancing the efficiency of gene editing
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
CA3028002A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
MA45491A (en) 2016-06-27 2019-05-01 Juno Therapeutics Inc CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
JP7033583B2 (en) 2016-07-13 2022-03-10 バーテックス ファーマシューティカルズ インコーポレイテッド Methods, compositions and kits for increasing genome editing efficiency
JP7490211B2 (en) 2016-07-19 2024-05-27 デューク ユニバーシティ Therapeutic Applications of CPF1-Based Genome Editing
CN114652735A (en) 2016-07-27 2022-06-24 凯斯西储大学 Compounds and methods for promoting myelination
JP7066126B2 (en) 2016-08-09 2022-05-13 ブイアイビー ブイゼットダブリュ Cellulose synthase inhibitors and mutant plants
LT3504229T (en) 2016-08-24 2021-12-10 Sangamo Therapeutics, Inc. Regulation of gene expression using engineered nucleases
SG11201901364VA (en) 2016-08-24 2019-03-28 Sangamo Therapeutics Inc Engineered target specific nucleases
JP7256739B2 (en) 2016-09-07 2023-04-12 サンガモ セラピューティクス, インコーポレイテッド Modulation of liver genes
US10400246B2 (en) 2016-10-03 2019-09-03 Dow Agrosciences Llc Plant promoter for transgene expression
EP3519433A1 (en) 2016-10-03 2019-08-07 Juno Therapeutics, Inc. Hpv-specific binding molecules
US10519459B2 (en) 2016-10-03 2019-12-31 Dow Agrosciences Llc Plant promoter from Panicum virgatum
CA3038690A1 (en) 2016-10-05 2018-04-12 FUJIFILM Cellular Dynamics, Inc. Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
WO2018071873A2 (en) 2016-10-13 2018-04-19 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
IL266047B2 (en) 2016-10-20 2025-02-01 Sangamo Therapeutics Inc Methods and preparations for the treatment of Fabry disease
JP7108608B2 (en) 2016-10-31 2022-07-28 サンガモ セラピューティクス, インコーポレイテッド Genetic modification of SCID-associated genes in hematopoietic stem and progenitor cells
IL266862B2 (en) 2016-12-01 2024-01-01 Sangamo Therapeutics Inc Tau modulators and methods and compositions for delivery thereof
AU2017367695A1 (en) 2016-12-02 2019-06-13 Juno Therapeutics, Inc. Engineered B cells and related compositions and methods
WO2018106732A1 (en) 2016-12-05 2018-06-14 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
JP7416406B2 (en) 2016-12-08 2024-01-17 ケース ウェスタン リザーブ ユニバーシティ Methods and compositions for increasing functional myelin production
AU2018224387B2 (en) 2017-02-22 2024-08-08 Crispr Therapeutics Ag Compositions and methods for gene editing
WO2018195418A1 (en) 2017-04-20 2018-10-25 Oregon Health & Science University Human gene correction
CA3059793A1 (en) 2017-05-03 2018-11-08 Sangamo Therapeutics, Inc. Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene
US11512287B2 (en) 2017-06-16 2022-11-29 Sangamo Therapeutics, Inc. Targeted disruption of T cell and/or HLA receptors
US10457955B2 (en) 2017-06-28 2019-10-29 Dow Agrosciences Llc Plant promoter for transgene expression
EP3665271A4 (en) 2017-08-08 2021-04-28 Sangamo Therapeutics, Inc. CELL TARGETING MEDIA BY A CHEMICAL ANTIGEN RECEPTOR
EP3692063A1 (en) 2017-10-03 2020-08-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
WO2019089982A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
JP2021502085A (en) 2017-11-09 2021-01-28 サンガモ セラピューティクス, インコーポレイテッド Genetic modification of cytokine-induced SH2-containing protein (CISH) gene
EP3717505A4 (en) 2017-12-01 2021-12-01 Encoded Therapeutics, Inc. MODIFIED DNA BINDING PROTEINS
US11459577B2 (en) 2017-12-18 2022-10-04 Syngenta Participations Ag Targeted insertion sites in the maize genome
EP4083192A1 (en) 2017-12-22 2022-11-02 Fate Therapeutics, Inc. Enhanced immune effector cells and use thereof
US12121524B2 (en) 2018-01-17 2024-10-22 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
KR20200110687A (en) 2018-01-17 2020-09-24 버텍스 파마슈티칼스 인코포레이티드 Quinoxalinone compounds, compositions, methods and kits for increasing genome editing efficiency
ES2980444T3 (en) 2018-01-17 2024-10-01 Vertex Pharma DNA-PK inhibitors
EP3740580A4 (en) 2018-01-19 2021-10-20 Duke University GENOMIC ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYOTES
WO2019157324A1 (en) 2018-02-08 2019-08-15 Sangamo Therapeutics, Inc. Engineered target specific nucleases
JP7575271B2 (en) 2018-03-29 2024-10-29 フェイト セラピューティクス,インコーポレイテッド Engineered immune effector cells and uses thereof
EP3775237A1 (en) 2018-04-05 2021-02-17 Juno Therapeutics, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
BR112020020245A2 (en) 2018-04-05 2021-04-06 Editas Medicine, Inc. METHODS OF PRODUCING CELLS EXPRESSING A RECOMBINANT RECEIVER AND RELATED COMPOSITIONS
MX2020010460A (en) 2018-04-05 2021-01-29 Juno Therapeutics Inc T-CELL RECEPTORS, AND ENGINEERED CELLS EXPRESSING THEM.
US11421007B2 (en) 2018-04-18 2022-08-23 Sangamo Therapeutics, Inc. Zinc finger protein compositions for modulation of huntingtin (Htt)
CN112105420A (en) 2018-05-11 2020-12-18 克里斯珀医疗股份公司 Methods and compositions for treating cancer
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
GB201809273D0 (en) 2018-06-06 2018-07-25 Vib Vzw Novel mutant plant cinnamoyl-coa reductase proteins
US20210337753A1 (en) 2018-06-07 2021-11-04 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization Methods of regenerating and transforming cannabis
EP3802839A1 (en) 2018-06-07 2021-04-14 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Nucleic acid constructs and methods of using same
CA3109592A1 (en) 2018-08-23 2020-02-27 Sangamo Therapeutics, Inc. Engineered target specific base editors
AU2019344927A1 (en) 2018-09-18 2021-04-01 Sangamo Therapeutics, Inc. Programmed cell death 1 (PD1) specific nucleases
IL322436A (en) 2018-09-21 2025-09-01 Acuitas Therapeutics Inc Systems and methods for manufacturing lipid nanoparticles and liposomes
KR20210070344A (en) 2018-10-02 2021-06-14 상가모 테라퓨틱스, 인코포레이티드 Methods and compositions for modulation of tau protein
WO2020095107A1 (en) 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-cd33 immune cell cancer therapy
JP7471289B2 (en) 2018-11-07 2024-04-19 クリスパー セラピューティクス アクチェンゲゼルシャフト Anti-LIV1 immune cell cancer therapy
KR20210092236A (en) 2018-11-07 2021-07-23 크리스퍼 테라퓨틱스 아게 Anti-PTK7 immune cell cancer therapy
SG11202105480WA (en) 2018-12-02 2021-06-29 Fate Therapeutics Inc IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
AU2019391114B2 (en) 2018-12-05 2026-01-29 Vertex Pharmaceuticals Incorporated Gene-editing systems for editing a cystic fibrosis transmembrane regulator (CFTR) gene
GB201820109D0 (en) 2018-12-11 2019-01-23 Vib Vzw Plants with a lignin trait and udp-glycosyltransferase mutation
CN113474328B (en) 2019-01-11 2025-07-11 爱康泰生治疗公司 Lipids for lipid nanoparticle delivery of active agents
US12156877B1 (en) 2019-01-15 2024-12-03 The Regents Of The University Of California Methods of treating conditions related to a thiamine deficiency, a thiamine-dependent enzyme, or an associated cofactor
CA3106693A1 (en) 2019-02-06 2020-08-13 Sangamo Therapeutics, Inc. Method for the treatment of mucopolysaccharidosis type i
WO2020185628A1 (en) 2019-03-08 2020-09-17 Obsidian Therapeutics, Inc. Cd40l compositions and methods for tunable regulation
CA3132167A1 (en) 2019-04-02 2020-10-08 Weston P. MILLER IV Methods for the treatment of beta-thalassemia
US12139517B2 (en) 2019-04-23 2024-11-12 Sangamo Therapeutics, Inc. Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
US20220184131A1 (en) 2019-05-01 2022-06-16 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
BR112021021200A2 (en) 2019-05-01 2021-12-21 Juno Therapeutics Inc Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides, and methods
KR102808368B1 (en) 2019-05-29 2025-05-15 엔코디드 테라퓨틱스, 인크. Compositions and methods for selective gene regulation
MA56388A (en) 2019-06-27 2022-05-04 Crispr Therapeutics Ag USE OF CHEMERA ANTIGEN RECEPTOR T LYMPHOCYTES AND NK CELL INHIBITORS FOR THE TREATMENT OF CANCER
AU2020314969A1 (en) 2019-07-17 2022-02-03 Fate Therapeutics, Inc. Immune effector cell engineering and use thereof
JP2022543112A (en) 2019-08-01 2022-10-07 サナ バイオテクノロジー,インコーポレイテッド DUX4-expressing cells and their uses
US20230025289A1 (en) 2019-08-23 2023-01-26 Sana Biotechnology, Inc. Cd24 expressing cells and uses thereof
US12344656B2 (en) 2019-09-06 2025-07-01 Crispr Therapeutics Ag Genetically engineered T cells having improved persistence in culture
WO2021067864A1 (en) 2019-10-02 2021-04-08 Sangamo Therapeutics, Inc. Zinc finger protein transcription factors for treatment of prion disease
AU2020356962A1 (en) 2019-10-02 2022-04-14 Sangamo Therapeutics, Inc. Zinc finger protein transcription factors for repressing alpha-synuclein expression
CN115279419A (en) 2019-11-01 2022-11-01 美商圣加莫治疗股份有限公司 Compositions and methods for genome engineering
TW202132565A (en) 2019-11-01 2021-09-01 美商聖加莫治療股份有限公司 Gin recombinase variants
US20230056856A1 (en) 2020-01-08 2023-02-23 Obsidian Therapeutics, Inc. Compositions and methods for tunable regulation of transcription
MX2022008953A (en) 2020-01-22 2022-08-15 Sangamo Therapeutics Inc Zinc finger protein transcription factors for repressing tau expression.
WO2021155065A1 (en) 2020-01-28 2021-08-05 The Broad Institute, Inc. Base editors, compositions, and methods for modifying the mitochondrial genome
KR20220158046A (en) 2020-03-25 2022-11-29 사나 바이오테크놀로지, 인크. Immunocompromised Neuronal Cells for Treatment of Nervous System Disorders and Conditions
US20230212613A1 (en) 2020-05-06 2023-07-06 Cellectis S.A. Methods for targeted insertion of exogenous sequences in cellular genomes
AU2021269103A1 (en) 2020-05-06 2022-12-15 Cellectis S.A. Methods to genetically modify cells for delivery of therapeutic proteins
CN115835873A (en) 2020-05-13 2023-03-21 朱诺治疗学股份有限公司 Method for producing donor batch cells expressing recombinant receptors
WO2021236852A1 (en) 2020-05-20 2021-11-25 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
WO2021247836A1 (en) 2020-06-03 2021-12-09 Board Of Regents, The University Of Texas System Methods for targeting shp-2 to overcome resistance
MX2022015863A (en) 2020-06-19 2023-03-23 Fate Therapeutics Inc Combining ipsc-derived effector cell types for immunotherapy use.
CN116234558A (en) 2020-06-26 2023-06-06 朱诺治疗学有限公司 Engineered T cells, related polynucleotides and methods for conditionally expressing recombinant receptors
EP4182297B1 (en) 2020-07-16 2025-09-03 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
MX2023001831A (en) 2020-08-13 2023-06-29 Sana Biotechnology Inc METHODS OF TREATMENT OF SENSITIZED PATIENTS WITH HYPOIMMUNOGENIC CELLS AND ASSOCIATED METHODS AND COMPOSITIONS.
EP4204545A2 (en) 2020-08-25 2023-07-05 Kite Pharma, Inc. T cells with improved functionality
IL301012A (en) 2020-09-23 2023-05-01 Crispr Therapeutics Ag Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence
WO2022067122A1 (en) 2020-09-25 2022-03-31 Sangamo Therapeutics, Inc. Zinc finger fusion proteins for nucleobase editing
IL301795A (en) 2020-10-02 2023-05-01 Sangamo Therapeutics Inc Novel zinc finger protein transcription factors for repressing alpha-synuclein expression
EP4240756A1 (en) 2020-11-04 2023-09-13 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
WO2022101641A1 (en) 2020-11-16 2022-05-19 Pig Improvement Company Uk Limited Influenza a-resistant animals having edited anp32 genes
MX2023006395A (en) 2020-12-03 2023-06-15 Century Therapeutics Inc GENETICALLY DESIGNED CELLS AND USES OF THESE.
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
WO2022137181A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Co-use of lenalidomide with car-t cells
MX2023006207A (en) 2020-12-31 2023-08-09 Sana Biotechnology Inc Methods and compositions for modulating car-t activity.
EP4305153A1 (en) 2021-03-09 2024-01-17 CRISPR Therapeutics AG Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity
US20250354978A1 (en) 2021-03-22 2025-11-20 Juno Therapeutics, Inc. Method to assess potency of viral vector particles
MX2023011927A (en) 2021-04-07 2023-10-23 Century Therapeutics Inc COMPOSITIONS AND METHODS FOR THE GENERATION OF GAMMA-DELTA T LYMPHOCYTES FROM INDUCED PLURIPOTENT STEM CELLS.
AU2022255166A1 (en) 2021-04-07 2023-09-28 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
EP4319799A1 (en) 2021-04-07 2024-02-14 Century Therapeutics, Inc. Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
CN117460820A (en) 2021-05-05 2024-01-26 富士胶片细胞动力公司 Methods and compositions regarding iPSC-derived microglia
CN117881777A (en) 2021-05-26 2024-04-12 富士胶片细胞动力公司 Method to prevent rapid gene silencing in pluripotent stem cells
JP2024521619A (en) 2021-05-27 2024-06-04 サナ バイオテクノロジー,インコーポレイテッド Hypoimmunogenic cells containing engineered HLA-E or HLA-G
US20240316198A1 (en) 2021-07-14 2024-09-26 Sana Biotechnology, Inc. Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
CA3227103A1 (en) 2021-07-30 2023-02-02 Matthew P. GEMBERLING Compositions and methods for modulating expression of frataxin (fxn)
EP4377460A1 (en) 2021-07-30 2024-06-05 Tune Therapeutics, Inc. Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
JP2024534772A (en) 2021-08-11 2024-09-26 サナ バイオテクノロジー,インコーポレイテッド Genetically modified cells for allogeneic cell therapy
WO2023019227A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
WO2023019225A2 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
TW202321435A (en) 2021-08-11 2023-06-01 美商薩那生物科技公司 Inducible systems for altering gene expression in hypoimmunogenic cells
EP4384189A1 (en) 2021-08-11 2024-06-19 Sana Biotechnology, Inc. Genetically modified primary cells for allogeneic cell therapy
AU2022344320A1 (en) 2021-09-10 2024-03-07 FUJIFILM Cellular Dynamics, Inc. Compositions of induced pluripotent stem cell-derived cells and methods of use thereof
WO2023042079A1 (en) 2021-09-14 2023-03-23 Crispr Therapeutics Ag Genetically engineered immune cells having a disrupted cd83 gene
EP4419676A1 (en) 2021-10-21 2024-08-28 Vertex Pharmaceuticals Incorporated Hypoimmune cells
EP4419117A1 (en) 2021-10-22 2024-08-28 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
WO2023076880A1 (en) 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Foxo1-targeted therapy for the treatment of cancer
CN118339279A (en) 2021-10-29 2024-07-12 富士胶片细胞动力公司 Dopaminergic neurons comprising mutations and methods of use thereof
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
WO2023105244A1 (en) 2021-12-10 2023-06-15 Pig Improvement Company Uk Limited Editing tmprss2/4 for disease resistance in livestock
WO2023111913A1 (en) 2021-12-15 2023-06-22 Crispr Therapeutics Ag Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
WO2023114943A2 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
EP4452304A1 (en) 2021-12-22 2024-10-30 CRISPR Therapeutics AG Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof
WO2023122722A1 (en) 2021-12-22 2023-06-29 Sangamo Therapeutics, Inc. Novel zinc finger fusion proteins for nucleobase editing
MX2024007528A (en) 2021-12-23 2024-08-30 Sana Biotechnology Inc CHIMERIC ANTIGEN RECEPTOR (CAR) T LYMPHOCYTES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND ASSOCIATED METHODS.
AU2022423987A1 (en) 2021-12-29 2024-07-11 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
EP4460571A1 (en) 2022-01-05 2024-11-13 Vib Vzw Means and methods to increase abiotic stress tolerance in plants
WO2023131637A1 (en) 2022-01-06 2023-07-13 Vib Vzw Improved silage grasses
CA3247928A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
WO2023137472A2 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
WO2023144199A1 (en) 2022-01-26 2023-08-03 Vib Vzw Plants having reduced levels of bitter taste metabolites
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
AU2023220128A1 (en) 2022-02-17 2024-08-22 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
TW202340457A (en) 2022-02-28 2023-10-16 美商凱特製藥公司 Allogeneic therapeutic cells
EP4486890A1 (en) 2022-03-01 2025-01-08 CRISPR Therapeutics AG Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
WO2023173123A1 (en) 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
WO2023180904A1 (en) 2022-03-21 2023-09-28 Crispr Therapeutics Ag Methods and compositions for treating lipoprotein-related diseases
WO2023180967A1 (en) 2022-03-23 2023-09-28 Crispr Therapeutics Ag Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption
TW202400778A (en) 2022-03-23 2024-01-01 瑞士商Crispr治療公司 Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof
JP7701453B2 (en) 2022-04-08 2025-07-01 フェイト セラピューティクス,インコーポレイティド Solid tumor targeting scaffold bearing cells and uses thereof
JP7707304B2 (en) 2022-04-08 2025-07-14 フェイト セラピューティクス,インコーポレイティド Chimeric antigen receptors for tumor targeting
WO2023230613A1 (en) 2022-05-27 2023-11-30 The Broad Institute, Inc. Improved mitochondrial base editors and methods for editing mitochondrial dna
WO2023240169A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof
US20250090582A1 (en) 2022-06-08 2025-03-20 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
CN119630695A (en) 2022-06-08 2025-03-14 世纪治疗股份有限公司 Genetically engineered cells expressing CD16 variants and NKG2D and uses thereof
AU2023290692A1 (en) 2022-06-17 2025-01-23 Crispr Therapeutics Ag LIPID NANOPARTICLES (LNPs)-BASED OCULAR DELIVERY
WO2023248145A1 (en) 2022-06-21 2023-12-28 Crispr Therapeutics Ag Compositions and methods for treating human immunodeficiency virus
US20250381304A1 (en) 2022-06-21 2025-12-18 Crispr Therapeutics Ag Methods and compositions for in vivo editing of stem cells
IL317874A (en) 2022-06-24 2025-02-01 Tune Therapeutics Inc Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
KR20250038661A (en) 2022-06-29 2025-03-19 후지필름 홀딩스 아메리카 코포레이션 IPSC-derived stellate cells and methods of using them
WO2024003786A1 (en) 2022-06-29 2024-01-04 Crispr Therapeutics Ag Chimeric antigen receptor targeting gpc-3 and immune cells expressing such for therapeutic uses
WO2024015881A2 (en) 2022-07-12 2024-01-18 Tune Therapeutics, Inc. Compositions, systems, and methods for targeted transcriptional activation
WO2024013514A2 (en) 2022-07-15 2024-01-18 Pig Improvement Company Uk Limited Gene edited livestock animals having coronavirus resistance
WO2024023804A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene
WO2024023801A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene
WO2024023802A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
AU2023325407A1 (en) 2022-08-19 2025-02-20 Tune Therapeutics, Inc. Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
JP2025531268A (en) 2022-09-19 2025-09-19 チューン セラピューティクス インコーポレイテッド Compositions, systems, and methods for modulating T cell function
WO2024062388A2 (en) 2022-09-20 2024-03-28 Crispr Therapeutics Ag Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20
WO2024102838A1 (en) 2022-11-09 2024-05-16 Century Therapeutics, Inc. Engineered interleukin-7 receptors and uses thereof
EP4615960A1 (en) 2022-11-09 2025-09-17 C3S2 GmbH Methods for manufacturing engineered immune cells
IL320650A (en) 2022-11-10 2025-07-01 Century Therapeutics Inc Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof
WO2024137677A1 (en) 2022-12-19 2024-06-27 FUJIFILM Holdings America Corporation Extracellular vesicle-enriched secretome composition derived from induced pluripotent stem cell derived-microglia and methods of use thereof
JP2026500040A (en) 2022-12-23 2026-01-05 エピジェニック セラピューティクス プライベート リミテッド Conjugates and their uses
TW202440931A (en) 2022-12-23 2024-10-16 大陸商益杰立科(上海)生物科技有限公司 Fusions and uses thereof
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
WO2024163678A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
WO2024163683A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
EP4658675A1 (en) 2023-02-03 2025-12-10 C3S2 GmbH Methods for non-viral manufacturing of engineered immune cells
WO2024173645A1 (en) 2023-02-15 2024-08-22 Arbor Biotechnologies, Inc. Gene editing method for inhibiting aberrant splicing in stathmin 2 (stmn2) transcript
WO2024192108A1 (en) 2023-03-14 2024-09-19 Evolveimmune Therapeutics, Inc. Genetically modified car t cells and methods of making and using the same
US20240366670A1 (en) 2023-04-21 2024-11-07 Kite Pharma, Inc. Allogenic therapeutic cells with reduced risk of immune rejection
WO2024229302A1 (en) 2023-05-03 2024-11-07 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
WO2024238726A1 (en) 2023-05-16 2024-11-21 Omega Therapeutics, Inc. Methods and compositions for modulating methylation of a target gene
WO2024238723A1 (en) 2023-05-16 2024-11-21 Omega Therapeutics, Inc. Methods and compositions for modulating pcsk9 expression
WO2024243236A2 (en) 2023-05-22 2024-11-28 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
WO2025004001A1 (en) 2023-06-30 2025-01-02 Takeda Pharmaceutical Company Limited Htt repressors and uses thereof
WO2025019742A1 (en) 2023-07-19 2025-01-23 Omega Therapeutics, Inc. Methods and compositions for modulating ctnnb1 expression
AU2024301706A1 (en) 2023-07-21 2026-02-05 Crispr Therapeutics Ag Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
WO2025029835A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for modulating il-2 gene expression
WO2025038494A1 (en) 2023-08-11 2025-02-20 Tune Therapeutics, Inc. Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
WO2025059073A1 (en) 2023-09-11 2025-03-20 Tune Therapeutics, Inc. Epigenetic editing methods and systems for differentiating stem cells
WO2025101938A2 (en) 2023-11-10 2025-05-15 Century Therapeutics, Inc. Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof
WO2025106626A1 (en) 2023-11-15 2025-05-22 Century Therapeutics, Inc. Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof
WO2025186726A1 (en) 2024-03-05 2025-09-12 Crispr Therapeutics Ag Modulating expression of agt (angiotensinogen) gene
WO2025194124A1 (en) 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. Modified st1cas9 guide nucleic acids
WO2025207795A1 (en) 2024-03-26 2025-10-02 Juno Therapeutics, Inc. Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof
WO2025207798A1 (en) 2024-03-26 2025-10-02 Century Therapeutics, Inc. Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof
WO2025235563A1 (en) 2024-05-07 2025-11-13 Omega Therapeutics, Inc. Epigenetic modulation for upregulation of genes
US20250345431A1 (en) 2024-05-10 2025-11-13 Juno Therapeutics, Inc. Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
WO2025260068A1 (en) 2024-06-14 2025-12-18 Tune Therapeutics, Inc. Lipid nanoparticle formulation for delivery of nucleic acids to cells
WO2026015647A1 (en) 2024-07-09 2026-01-15 Tune Therapeutics, Inc. Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4014808A (en) * 1973-06-04 1977-03-29 Tennant Company Detergent composition
GB8723776D0 (en) * 1987-10-09 1987-11-11 Procter & Gamble Ltd Toilet compositions
GB8811953D0 (en) * 1988-05-20 1988-06-22 Unilever Plc General-purpose cleaning compositions
JP2523837B2 (en) * 1988-11-25 1996-08-14 花王株式会社 Detergent composition for flush toilet
GB8914462D0 (en) * 1989-06-23 1989-08-09 Unilever Plc Cleaning composition
JP2952555B2 (en) * 1993-12-28 1999-09-27 花王株式会社 Hard surface cleaning composition
JP3347250B2 (en) * 1995-12-20 2002-11-20 花王株式会社 Antifouling detergent composition for toilet
JP3441885B2 (en) * 1996-06-14 2003-09-02 花王株式会社 Toilet cleaner composition
JPH10195498A (en) * 1996-12-27 1998-07-28 Lion Corp Liquid detergent composition
US5858939A (en) * 1997-03-21 1999-01-12 Lever Brothers Company, Division Of Conopco, Inc. Method for preparing bars comprising use of separate bar adjuvant compositions comprising benefit agent and deposition polymer
JP3025757B2 (en) * 1997-09-02 2000-03-27 花王株式会社 Disinfectant cleaning composition for floors
PL188065B1 (en) * 1997-09-12 2004-12-31 Izabella Bogacka Method of obtaining daily personal hygiene agents
JP2002527575A (en) * 1998-10-13 2002-08-27 ザ、プロクター、エンド、ギャンブル、カンパニー Laundry detergent composition having cationically charged dye-retaining polymer
HUP0203811A3 (en) * 1999-12-08 2005-10-28 Unilever Nv Use of polymeric material in the treatment of hard surfaces

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004075789A (en) * 2002-08-14 2004-03-11 Kao Corp Cleaning composition for hard surfaces
JP2004155803A (en) * 2002-11-01 2004-06-03 Kao Corp Solid detergent composition for flush toilet
JP2005029756A (en) * 2003-07-11 2005-02-03 Kao Corp Toilet cleaner
JP2005029754A (en) * 2003-07-11 2005-02-03 Kao Corp Aqueous liquid composition
WO2008054009A1 (en) 2006-10-31 2008-05-08 Kao Corporation Bleaching agent composition
JP2008133453A (en) * 2006-10-31 2008-06-12 Kao Corp Bleach composition
JP2008266375A (en) * 2007-04-17 2008-11-06 Johnson Diversey Co Ltd Cleaning composition for hard surface
JP2010168428A (en) * 2009-01-20 2010-08-05 Kao Corp Liquid detergent composition for hard surface
JP2011246677A (en) * 2010-05-31 2011-12-08 Ueno Fine Chem Ind Ltd Cleaning-sterilizing agent composition
JP2012092320A (en) * 2010-09-28 2012-05-17 Kobayashi Pharmaceutical Co Ltd Biofilm removing agent, composition for removing biofilm, and method for removing biofilm
JP2012111846A (en) * 2010-11-25 2012-06-14 Dainippon Jochugiku Co Ltd Acidic antibacterial detergent composition
JP2017048238A (en) * 2010-12-31 2017-03-09 バイオトロル・ピーエルシー Antimicrobial composition
JP2019006832A (en) * 2010-12-31 2019-01-17 ロディア オペレーションズRhodia Operations Antimicrobial composition
JP2012193287A (en) * 2011-03-17 2012-10-11 Adeka Corp Detergent composition for oil stain
JP2012255073A (en) * 2011-06-08 2012-12-27 Kao Corp Liquid detergent composition for hard surface
JP2013023642A (en) * 2011-07-25 2013-02-04 Dainippon Jochugiku Co Ltd Rinse accelerator for hard surface detergent
JP2015507676A (en) * 2011-12-29 2015-03-12 バイオトロル・ピーエルシー Antimicrobial composition
JP2021008633A (en) * 2011-12-29 2021-01-28 ローディア オペレーションズ Antimicrobial composition
JP2014009349A (en) * 2012-07-03 2014-01-20 Kao Corp Liquid aroma composition for flush toilet
JP2015113455A (en) * 2013-12-16 2015-06-22 花王株式会社 Sterilizing detergent composition for hard surfaces
WO2015093164A1 (en) * 2013-12-16 2015-06-25 花王株式会社 Bactericidal cleaning composition for hard surfaces
TWI615465B (en) * 2013-12-16 2018-02-21 Kao Corp Sterilizing detergent composition for hard surfaces
JP2016124965A (en) * 2014-12-26 2016-07-11 ライオン株式会社 Liquid cleaner for bathroom
JP2019156999A (en) * 2018-03-14 2019-09-19 株式会社ニイタカ Detergent composition, spray bottle, wet wiper, and deodorization and sterilization cleaning method
JP7075655B2 (en) 2018-03-14 2022-05-26 株式会社ニイタカ Detergent composition, spray bottle, wet wiper and deodorant disinfectant cleaning method
US10980230B2 (en) 2018-04-09 2021-04-20 Rhodia Operations Compositions and methods for long lasting disinfection
CN112203513A (en) * 2018-04-09 2021-01-08 罗地亚经营管理公司 Compositions and methods for durable disinfection
WO2019199886A1 (en) * 2018-04-09 2019-10-17 Rhodia Operations Compositions and methods for long lasting disinfection
US11877575B2 (en) 2018-04-09 2024-01-23 Rhodia Operations Compositions and methods for long lasting disinfection
EP4464159A3 (en) * 2018-04-09 2025-02-26 Specialty Operations France Compositions and methods for long lasting disinfection
JP2020041074A (en) * 2018-09-12 2020-03-19 ライオン株式会社 Liquid detergent composition for clothing
JP2020100691A (en) * 2018-12-20 2020-07-02 中国塗料株式会社 Antifouling coat composition, antifouling coat film, base material with antifouling coat film, antifouling method for base material and method for producing base material with antifouling coat film
JP7335068B2 (en) 2018-12-20 2023-08-29 中国塗料株式会社 Antifouling paint composition, antifouling coating film, substrate with antifouling coating film, antifouling method for substrate, and method for producing substrate with antifouling coating film
JP2020152856A (en) * 2019-03-22 2020-09-24 株式会社Adeka Cleaning agent composition for hard surface and cleaning method for hard surface

Also Published As

Publication number Publication date
TWI283267B (en) 2007-07-01
WO2002016536A1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
JP2002060786A (en) Bactericidal antifouling agent for hard surfaces
JP2003096493A (en) Disinfectant antifouling detergent for hard surfaces
EP1196523B1 (en) Cleansing composition comprising a water soluble or water dispersible polymer
JP4230153B2 (en) Antifouling cleaner for hard surfaces
CN100575472C (en) Hard Surface Cleaner
JP3422978B2 (en) Cleaning composition for hard surfaces
US7544649B2 (en) Antifouling detergent for hard surfaces
JP5342126B2 (en) Bleach composition
JP4008364B2 (en) Antifouling cleaner for hard surfaces
JP5575466B2 (en) Cleaning composition for hard surface
JP2002348596A (en) Detergent composition
JP4907327B2 (en) Detergent composition for dishwasher
JP2002146395A (en) Cleaning composition for hard surfaces
JP5234701B2 (en) Cleaning composition for hard surface
JP3986846B2 (en) Concentrated liquid detergent for flush toilet
JP6093280B2 (en) Liquid detergent composition for hard surfaces
JP3405970B2 (en) Cleaning composition for hard surfaces
JP3558907B2 (en) Hard surface antifouling antibacterial detergent composition
JP4912859B2 (en) Dishwasher finish composition
JP2004155803A (en) Solid detergent composition for flush toilet
JP4040326B2 (en) Concentrated liquid detergent for flush toilet
JP6093279B2 (en) Liquid detergent composition for hard surfaces
JP2001152199A (en) Liquid detergent composition
JP4732064B2 (en) Cleaning composition for hard surface
JP2002531634A (en) Safe cleaning method for enamel